



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 5/00, 5/10, 5/16, 15/00, 15/09</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/41615</b> <b>(43) International Publication Date:</b> 24 September 1998 (24.09.98)
<b>(21) International Application Number:</b> PCT/US98/05376 <b>(22) International Filing Date:</b> 18 March 1998 (18.03.98) <b>(30) Priority Data:</b> 08/821,984                      20 March 1997 (20.03.97)                      US <b>(71) Applicant:</b> WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, Madison, WI 53705-7365 (US). <b>(72) Inventors:</b> BREMEL, Robert, D.; E3352 Chapel Road, Hillpoint, WI 53937 (US). CHAN, Anthony, W., S.; Apartment #9, 150 Ninth Street, Prairie du Sac, WI 53578 (US). BURNS, Jane, C.; 6506 El Camino del Teatro, La Jolla, CA 92037 (US). <b>(74) Agents:</b> MACKNIGHT, Kamrin, T. et al.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS FOR CREATING TRANSGENIC ANIMALS  <b>(57) Abstract</b>  <p>The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## METHODS FOR CREATING TRANSGENIC ANIMALS

This invention was made with United States government support awarded by the U.S. Department of Agriculture Hatch Project #3669. The Government of the United States of America has certain rights in the invention.

### FIELD OF THE INVENTION

The present invention relates to improved methods for the generation of transgenic non-human animals. In particular, the present invention relates to the introduction of retroviral particles into the perivitelline space of gametes, zygotes and early stage embryos to allow the insertion of genetic material into the genome of the recipient gamete or embryo.

### BACKGROUND

The ability to alter the genetic make-up of animals, such as domesticated mammals such as cows, pigs and sheep, allows a number of commercial applications. These applications include the production of animals which express large quantities of exogenous proteins in an easily harvested form (e.g., expression into the milk), the production of animals which are resistant to infection by specific microorganisms and the production of animals having enhanced growth rates or reproductive performance. Animals which contain exogenous DNA sequences in their genome are referred to as transgenic animals.

The most widely used method for the production of transgenic animals is the microinjection of DNA into the pronuclei of fertilized embryos. This method is efficient for the production of transgenic mice but is much less efficient for the production of transgenic animals using large mammals such as cows and sheep. For example, it has been reported that 1,000 to 2,000 bovine embryos at the pronuclear stage must be microinjected to produce a single transgenic cow at an estimate cost of more than \$500,000 [Wall *et al.* (1992) J. Cell. Biochem. 49:113]. Furthermore, microinjection of pronuclei is more difficult when embryos from domestic livestock (e.g., cattle, sheep, pigs) is employed as the pronuclei are often obscured by yolk material. While techniques for the visualization of the pronuclei are known (i.e., centrifugation of the embryo to sediment the yolk), the injection of pronuclei is an invasive technique which requires a high degree of operator skill.

Alternative methods for the production include the infection of embryos with retroviruses or with retroviral vectors. Infection of both pre- and post-implantation mouse

embryos with either wild-type or recombinant retroviruses has been reported [Janenich (1976) *Proc. Natl. Acad. Sci. USA* 73:1260-1264; Janenich *et al.* (1981) *Cell* 24:519; Stuhlmann *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:7151; Jahner *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82:6927-6931; Van der Putten, *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82:6148-6152; Stewart, *et al.* (1987) *EMBO J.* 6:383-388]. The resulting transgenic animals are typically mosaic for the transgene since incorporation occurs only in a subset of cells which form the transgenic animal. The consequences of mosaic incorporation of retroviral sequences (*i.e.*, the transgene) include lack of transmission of the transgene to progeny due to failure of the retrovirus to integrate into the germ line, difficulty in detecting the presence of viral sequences in the founder mice in those cases where the infected cell contributes to only a small part of the fetus and difficulty in assessing the effect of the genes carried on the retrovirus.

In addition to the production of mosaic founder animals, infection of embryos with retrovirus (which is typically performed using embryos at the 8 cell stage or later) often results in the production of founder animals containing multiple copies of the retroviral provirus at different positions in the genome which generally will segregate in the offspring. Infection of early mouse embryos by co-culturing early embryos with cells producing retroviruses requires enzymatic treatment to remove the zona pellucida [Hogan *et al.* (1994) in *Manipulating the Mouse Embryo: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 251-252]. In contrast to mouse embryos, bovine embryos dissociate when removed from the zona pellucida. Therefore, infection protocols which remove the zona pellucida cannot be employed for the production of transgenic cattle or other animals whose embryos dissociate or suffer a significant decrease in viability upon removal of the zona pellucida (*e.g.*, ovine embryos).

An alternative means for infecting embryos with retroviruses is the injection of virus or virus-producing cells into the blastocoele of mouse embryos [Jahner, D. *et al.* (1982) *Nature* 298:623-628]. As is the case for infection of eight cell stage embryos, most of the founders produced by injection into the blastocoele will be mosaic. The introduction of transgenes into the germline of mice has been reported using intrauterine retroviral infection of the midgestation mouse embryo [Jahner, D. *et al.* (1982) *supra*]. This technique suffers from a low efficiency of generation of transgenic animals and in addition produces animals which are mosaic for the transgene.

Infection of bovine and ovine embryos with retroviruses or retroviral vectors to create transgenic animals has been reported. These protocols involve the micro-injection of retroviral particles or growth arrested (*i.e.*, mitomycin C-treated) cells which shed retroviral particles into the perivitelline space of fertilized eggs or early embryos [PCT International Application WO 90/08832 (1990) and Haskell and Bowen (1995) Mol. Reprod. Dev. 40:386].  
5 PCT International Application WO 90/08832 describes the injection of wild-type feline leukemia virus B into the perivitelline space of sheep embryos at the 2 to 8 cell stage. Fetuses derived from injected embryos were shown to contain multiple sites of integration. The efficiency of producing transgenic sheep was low (efficiency is defined as the number of  
10 transgenics produced compared to the number of embryos manipulated); only 4.2% of the injected embryos were found to be transgenic.

Haskell and Bowen (*supra*) describe the micro-injection of mitomycin C-treated cells producing retrovirus into the perivitelline space of 1 to 4 cell bovine embryos. The use of virus-producing cells precludes the delivery of a controlled amount of viral particles per  
15 embryo. The resulting fetuses contained between 2 and 12 proviruses and were shown to be mosaic for proviral integration sites, the presence of provirus, or both. The efficiency of producing transgenic bovine embryos was low; only 7% of the injected embryos were found to be transgenic.

The art needs improved methods for the production of transgenic animals, particularly  
20 for the production of transgenics using large domestic livestock animals. The ideal method would be simple to perform and less invasive than pronuclear injection, efficient, would produce mosaic transgenic founder animals at a low frequency and would result in the integration of a defined number of copies of the introduced sequences into the genome of the transgenic animal.

25

## SUMMARY OF THE INVENTION

The present invention provides improved methods and compositions for the production of transgenic non-human animals. In one embodiment, the present invention provides a composition comprising a non-human unfertilized oocyte comprising a heterologous  
30 oligonucleotide (*i.e.*, a heterologous polynucleotide) integrated into the genome of the oocyte. In a preferred embodiment the unfertilized oocyte is a pre-maturation oocyte. In another preferred embodiment the unfertilized oocyte is a pre-fertilization oocyte. The present invention is not limited by the nature of the heterologous oligonucleotide contained within the

genome of the oocyte. In a preferred embodiment, the heterologous oligonucleotide is the proviral form of a retroviral vector.

The invention is not limited by the nature of the retroviral vector employed. Retroviral vectors containing a variety of genes may be employed. For example, the  
5 retroviral vector may contain sequences encoding proteins which modify growth rate, size and/or carcass composition (*e.g.*, bovine growth hormone or other growth hormones) or foreign proteins of commercial value that are expressed in, and harvested from, a particular tissue component (*e.g.*, blood or milk). The retroviral vector may contain genes that confer  
10 disease resistance to viruses or other microorganisms, including DNA sequences that are transcribed into RNA sequences that catalytically cleave specific RNAs (*i.e.*, ribozymes) such as viral RNAs and DNA sequences that are transcribed into anti-sense RNA of an essential gene of a pathogenic microorganism. The above protein-encoding genes and DNA sequences are examples of "genes of interest."

The compositions of the present invention are not limited by the nature of the non-  
15 human animal employed to provide oocytes. In a preferred embodiment, the non-human animal is a mammal (*e.g.*, cows, pigs, sheep, goats, rabbits, rats, mice, etc.). In a particularly preferred embodiment, the non-human animal is a cow.

The present invention further provides a method for introducing a heterologous polynucleotide into the genome of a non-human unfertilized oocyte, comprising: a)  
20 providing: i) a non-human unfertilized egg comprising an oocyte having a plasma membrane and a zona pellucida, the plasma membrane and the zona pellucida defining a perivitelline space; ii) an aqueous solution comprising a heterologous polynucleotide; and b) introducing the solution comprising the heterologous polynucleotide into the perivitelline space under conditions which permit the introduction of the heterologous polynucleotide into the genome  
25 of the oocyte. The method of the present invention is not limited by the nature of the heterologous polynucleotide employed. In a preferred embodiment, the heterologous polynucleotide encodes a protein of interest. In a particularly preferred embodiment, the heterologous polynucleotide is contained within genome of a recombinant retrovirus.

The method of the present invention may be practiced using unfertilized eggs  
30 comprising a pre-maturation oocyte. Alternatively, the method of the present invention may employ pre-fertilization oocytes as the unfertilized egg.

When a recombinant retrovirus is employed infectious retroviral particles comprising the heterologous polynucleotide are preferentially employed. The method of the present

invention is not limited by the nature of the infectious retrovirus employed to deliver nucleic acid sequences to an oocyte. Any retrovirus which is capable of infecting the species of oocyte to be injected may be employed. In a preferred embodiment, the infectious retrovirus comprises a heterologous membrane-associated protein. In a preferred embodiment, the  
5 heterologous membrane-associated protein is a G glycoprotein selected from a virus within the family Rhabdoviridae. In another preferred embodiment, the heterologous membrane-associated protein is selected from the group consisting of the G glycoprotein of vesicular stomatitis virus, Piry virus, Chandipura virus, Spring viremia of carp virus and Mokola virus. In a particularly preferred embodiment, the heterologous membrane-associated protein is the  
10 G glycoprotein of vesicular stomatitis virus.

The method of the present invention is not limited by the nature of the non-human animal employed to provide oocytes. In a preferred embodiment, the non-human animal is a mammal (*e.g.*, cows, pigs, sheep, goats, rabbits, rats, mice, etc.). In a particularly preferred embodiment, the non-human animal is a cow.

15 The present invention further provides a method for the production of a transgenic non-human animal comprising: a) providing: i) an unfertilized egg comprising an oocyte having a plasma membrane and a zona pellucida, the plasma membrane and the zona pellucida defining a perivitelline space; ii) an aqueous solution containing infectious retrovirus; b) introducing the solution containing infectious retrovirus into the perivitelline  
20 space under conditions which permit the infection of the oocyte; and c) contacting the infected oocyte with sperm under conditions which permit the fertilization of the infected oocyte to produce an embryo. In a preferred embodiment, the method of the present invention further comprises, following the fertilization of the infected oocyte, the step of transferring the embryo into a hormonally synchronized non-human recipient animal (*i.e.*, a  
25 female animal hormonally synchronized to stimulate early pregnancy). In another preferred embodiment, the method comprises the step of allowing the transferred embryo to develop to term. In still another referred embodiment, at least one transgenic offspring is identified from the offspring allowed to develop to term.

The method of the present invention may be practiced using unfertilized eggs  
30 comprising a pre-maturation oocyte. Alternatively, the method of the present invention may employ pre-fertilization oocytes as the unfertilized egg.

When pre-maturation oocytes are employed in the method of the present invention, the method may further comprise, following the introduction of the solution containing infectious

retrovirus into the pre-maturation oocyte, the further step of culturing the infected pre-maturation oocyte under conditions which permit the maturation of the pre-maturation oocyte. The art is well aware of culture conditions which permit the *in vitro* maturation of pre-maturation oocytes from a variety of mammalian species.

5           The method of the present invention is not limited by the nature of the infectious retrovirus employed to deliver nucleic acid sequences to an oocyte. Any retrovirus which is capable of infecting the species of oocyte to be injected may be employed. In a preferred embodiment, the infectious retrovirus comprises a heterologous membrane-associated protein. In a preferred embodiment, the heterologous membrane-associated protein is a G glycoprotein selected from a virus within the family Rhabdoviridae. In another preferred embodiment, the heterologous membrane-associated protein is selected from the group consisting of the G glycoprotein of vesicular stomatitis virus, Piry virus, Chandipura virus, Spring viremia of carp virus and Mokola virus. In a particularly preferred embodiment, the heterologous membrane-associated protein is the G glycoprotein of vesicular stomatitis virus.

15           The method of the present invention is not limited by the nature of the non-human animal employed to provide oocytes. In a preferred embodiment, the non-human animal is a mammal (*e.g.*, cows, pigs, sheep, goats, rabbits, rats, mice, etc.). In a particularly preferred embodiment, the non-human animal is a cow.

## 20       **DESCRIPTION OF THE DRAWINGS**

Figure 1 provides a schematic showing the production of pre-maturation oocytes, pre-fertilization oocytes and fertilized oocytes (zygotes).

Figure 2 shows an autoradiogram of a Southern blot of genomic DNA isolated from the skin (A) and blood (B) of calves derived from pre-fertilization oocytes and zygotes which were injected with pseudotyped LSRNL retrovirus.

Figure 3 shows an ethidium bromide stained agarose gel containing electrophoresed PCR products which were amplified using *neo* gene primers (A) or *HBsAg* primers (B) from the blood and skin of calves derived from pre-fertilization oocytes and zygotes injected with pseudotyped LSRNL retrovirus.

30



**DEFINITIONS**

To facilitate understanding of the invention, a number of terms are defined below.

As used herein, the term "egg" when used in reference to a mammalian egg, means an oocyte surrounded by a zona pellucida and a mass of cumulus cells (follicle cells) with their associated proteoglycan. The term "egg" is used in reference to eggs recovered from antral follicles in an ovary (these eggs comprise pre-maturation oocytes) as well as to eggs which have been released from an antral follicle (a ruptured follicle).

As used herein, the term "oocyte" refers to a female gamete cell and includes primary oocytes, secondary oocytes and mature, unfertilized ovum. An oocyte is a large cell having a large nucleus (*i.e.*, the germinal vesicle) surrounded by ooplasm. The ooplasm contains non-nuclear cytoplasmic contents including mRNA, ribosomes, mitochondria, yolk proteins, etc. The membrane of the oocyte is referred to herein as the "plasma membrane."

The term "pre-maturation oocyte" as used herein refers to a female gamete cell following the oogonia stage (*i.e.*, mitotic proliferation has occurred) that is isolated from an ovary (*e.g.*, by aspiration) but which has not been exposed to maturation medium *in vitro*. Those of skill in the art know that the process of aspiration causes oocytes to begin the maturation process but that completion of the maturation process (*i.e.*, formation of a secondary oocyte which has extruded the first polar body) *in vitro* requires the exposure of the aspirated oocytes to maturation medium. Pre-maturation oocytes will generally be arrested at the first anaphase of meiosis.

The term "pre-fertilization oocyte" as used herein refers to a female gamete cell such as a pre-maturation oocyte following exposure to maturation medium *in vitro* but prior to exposure to sperm (*i.e.*, matured but not fertilized). The pre-fertilization oocyte has completed the first meiotic division, has released the first polar body and lacks a nuclear membrane (the nuclear membrane will not reform until fertilization occurs; after fertilization, the second meiotic division occurs along with the extrusion of the second polar body and the formation of the male and female pronuclei). Pre-fertilization oocytes may also be referred to as matured oocytes at metaphase II of the second meiosis.

The terms "unfertilized egg" or "unfertilized oocyte" as used herein refers to any female gamete cell which has not been fertilized and these terms encompass both pre-maturation and pre-fertilization oocytes.

The term "perivitelline space" refers to the space located between the zona pellucida and the plasma membrane of a mammalian egg or oocyte.

The term "infectious retrovirus" refers to a retroviral particle which is capable of entering a cell (*i.e.*, the particle contains a membrane-associated protein such as an envelope protein or a viral G glycoprotein which can bind to the host cell surface and facilitate entry of the viral particle into the cytoplasm of the host cell) and integrating the retroviral genome (as a double-stranded provirus) into the genome of the host cell.

Retroviral vectors can be used to transfer genes efficiently into host cells by exploiting the viral infectious process. Foreign or heterologous genes cloned (*i.e.*, inserted using molecular biological techniques) into the retroviral genome can be delivered efficiently to host cells which are susceptible to infection by the retrovirus. Through well known genetic manipulations, the replicative capacity of the retroviral genome can be destroyed. The resulting replication-defective vectors can be used to introduce new genetic material to a cell but they are unable to replicate. A helper virus or packaging cell line can be used to permit vector particle assembly and egress from the cell.

The terms "vector particle" or "retroviral particle" refer to viral-like particles that are capable of introducing nucleic acid into a cell through a viral-like entry mechanism.

The host range of a retroviral vector (*i.e.*, the range of cells that these vectors can infect) can be altered by including an envelope protein from another closely related virus.

The term "membrane-associated protein" refers to a protein (*e.g.*, a viral envelope glycoprotein or the G proteins of viruses in the Rhabdoviridae family such as VSV, Piry, Chandipura and Mokola) which are associated with the membrane surrounding a viral particle; these membrane-associated proteins mediate the entry of the viral particle into the host cell. The membrane associated protein may bind to specific cell surface protein receptors, as is the case for retroviral envelope proteins or the membrane-associated protein may interact with a phospholipid component of the plasma membrane of the host cell, as is the case for the G proteins derived from members of the Rhabdoviridae family.

The term "heterologous membrane-associated protein" refers to a membrane-associated protein which is derived from a virus which is not a member of the same viral class or family as that from which the nucleocapsid protein of the vector particle is derived. "Viral class or family" refers to the taxonomic rank of class or family, as assigned by the International Committee on Taxonomy of Viruses.

The term "Rhabdoviridae" refers to a family of enveloped RNA viruses that infect animals, including humans, and plants. The Rhabdoviridae family encompasses the genus Vesiculovirus which includes vesicular stomatitis virus (VSV), Cocal virus, Piry virus,

Chandipura virus, and Spring viremia of carp virus (sequences encoding the Spring viremia of carp virus are available under GenBank accession number U18101). The G proteins of viruses in the Vesiculovirus genera are virally-encoded integral membrane proteins that form externally projecting homotrimeric spike glycoproteins complexes that are required for receptor binding and membrane fusion. The G proteins of viruses in the Vesiculovirus genera have a covalently bound palmitic acid (C<sub>16</sub>) moiety. The amino acid sequences of the G proteins from the Vesiculoviruses are fairly well conserved. For example, the Piry virus G protein share about 38% identity and about 55% similarity with the VSV G proteins (several strains of VSV are known, e.g., Indiana, New Jersey, Orsay, San Juan, etc., and their G proteins are highly homologous). The Chandipura virus G protein and the VSV G proteins share about 37% identity and 52% similarity. Given the high degree of conservation (amino acid sequence) and the related functional characteristics (e.g., binding of the virus to the host cell and fusion of membranes, including syncytia formation) of the G proteins of the Vesiculoviruses, the G proteins from non-VSV Vesiculoviruses may be used in place of the VSV G protein for the pseudotyping of viral particles. The G proteins of the Lyssa viruses (another genera within the Rhabdoviridae family) also share a fair degree of conservation with the VSV G proteins and function in a similar manner (e.g., mediate fusion of membranes) and therefore may be used in place of the VSV G protein for the pseudotyping of viral particles. The Lyssa viruses include the Mokola virus and the Rabies viruses (several strains of Rabies virus are known and their G proteins have been cloned and sequenced). The Mokola virus G protein shares stretches of homology (particularly over the extracellular and transmembrane domains) with the VSV G proteins which show about 31% identity and 48% similarity with the VSV G proteins. Preferred G proteins share at least 25% identity, preferably at least 30% identity and most preferably at least 35% identity with the VSV G proteins. The VSV G protein from which New Jersey strain (the sequence of this G protein is provided in GenBank accession numbers M27165 and M21557) is employed as the reference VSV G protein.

The term "conditions which permit the maturation of a pre-maturation oocyte" refers to conditions of *in vitro* cell culture which permit the maturation of a pre-maturation oocyte to a mature ovum (e.g., a pre-fertilization oocyte). These culture conditions permit and induce the events which are associated with maturation of the pre-maturation oocyte including stimulation of the first and second meiotic divisions. *In vitro* culture conditions which permit the maturation of pre-maturation oocytes from a variety of mammalian species (e.g., cattle,

hamster, pigs and goats) are well known to the art [see e.g., Parrish *et al.* (1985) *Theriogenology* 24:537; Rosenkrans and First (1994) *J. Ani. Sci.* 72:434; Bavister and Yanagimachi (1977) *Biol. Reprod.* 16:228; Bavister *et al.* (1983) *Biol. Reprod.* 28:235; Leibfried and Bavister (1982) *J. Reprod. Fert.* 66:87; Keskinetepe *et al.* (1994) *Zygote* 2:97  
5 Funahashi *et al.* (1994) *J. Reprod. Fert.* 101:159 and Funahashi *et al.* (1994) *Biol. Reprod.* 50:1072].

## DESCRIPTION OF THE INVENTION

The present invention provides improved methods for the production of transgenic  
10 animals. The methods of the present invention provide, for the first time, the production of transgenic animals by the introduction of exogenous DNA into pre-maturation oocytes and mature, unfertilized oocytes (*i.e.*, pre-fertilization oocytes) using retroviral vectors which transduce dividing cells [*e.g.*, vectors derived from murine leukemia virus (MLV)].

The Description of the Invention is divided into the following sections: I. Retroviruses  
15 and Retroviral Vectors; II. Integration of Retroviral DNA; III. Introduction of Retroviral Vectors Into Gametes Before the Last Meiotic Division; and IV. Detection of the Retrovirus Following Injection Into Oocytes or Embryos.

### I. Retroviruses and Retroviral Vectors

20 Retroviruses (family Retroviridae) are divided into three groups: the spumaviruses (*e.g.*, human foamy virus); the lentiviruses (*e.g.*, human immunodeficiency virus and sheep visna virus) and the oncoviruses (*e.g.*, MLV, Rous sarcoma virus).

Retroviruses are enveloped (*i.e.*, surrounded by a host cell-derived lipid bilayer membrane) single-stranded RNA viruses which infect animal cells. When a retrovirus infects  
25 a cell, its RNA genome is converted into a double-stranded linear DNA form (*i.e.*, it is reverse transcribed). The DNA form of the virus is then integrated into the host cell genome as a provirus. The provirus serves as a template for the production of additional viral genomes and viral mRNAs. Mature viral particles containing two copies of genomic RNA bud from the surface of the infected cell. The viral particle comprises the genomic RNA,  
30 reverse transcriptase and other *pol* gene products inside the viral capsid (which contains the viral *gag* gene products) which is surrounded by a lipid bilayer membrane derived from the host cell containing the viral envelope glycoproteins (also referred to as membrane-associated proteins).

The organization of the genomes of numerous retroviruses is well known to the art and this has allowed the adaptation of the retroviral genome to produce retroviral vectors. The production of a recombinant retroviral vector carrying a gene of interest is typically achieved in two stages. First, the gene of interest is inserted into a retroviral vector which  
5 contains the sequences necessary for the efficient expression of the gene of interest [including promoter and/or enhancer elements which may be provided by the viral long terminal repeats (LTRs) or by an internal promoter/enhancer and relevant splicing signals], sequences required for the efficient packaging of the viral RNA into infectious virions [*e.g.*, the packaging signal (Psi), the tRNA primer binding site (-PBS), the 3' regulatory sequences required for reverse  
10 transcription (+PBS)] and the viral LTRs. The LTRs contain sequences required for the association of viral genomic RNA, reverse transcriptase and integrase functions, and sequences involved in directing the expression of the genomic RNA to be packaged in viral particles. For safety reasons, many recombinant retroviral vectors lack functional copies of the genes which are essential for viral replication (these essential genes are either deleted or  
15 disabled); the resulting virus is said to be replication defective.

Second, following the construction of the recombinant vector, the vector DNA is introduced into a packaging cell line. Packaging cell lines provide viral proteins required in *trans* for the packaging of the viral genomic RNA into viral particles having the desired host range (*i.e.*, the viral-encoded gag, pol and env proteins). The host range is controlled, in part,  
20 by the type of envelope gene product expressed on the surface of the viral particle. Packaging cell lines may express ecotropic, amphotropic or xenotropic envelope gene products. Alternatively, the packaging cell line may lack sequences encoding a viral envelope (env) protein. In this case the packaging cell line will package the viral genome into particles which lack a membrane-associated protein (*e.g.*, an env protein). In order to produce viral  
25 particles containing a membrane associated protein which will permit entry of the virus into a cell, the packaging cell line containing the retroviral sequences is transfected with sequences encoding a membrane-associated protein [*e.g.*, the G protein of vesicular stomatitis virus (VSV)]. The transfected packaging cell will then produce viral particles which contain the membrane-associated protein expressed by the transfected packaging cell line; these viral  
30 particles which contain viral genomic RNA derived from one virus encapsidated by the envelope proteins of another virus are said to be pseudotyped virus particles.

Viral vectors, including recombinant retroviral vectors, provide a more efficient means of transferring genes into cells as compared to other techniques such as calcium

phosphate-DNA co-precipitation or DEAE-dextran-mediated transfection, electroporation or microinjection of nucleic acids. It is believed that the efficiency of viral transfer is due in part to the fact that the transfer of nucleic acid is a receptor-mediated process (*i.e.*, the virus binds to a specific receptor protein on the surface of the cell to be infected). In addition, the virally transferred nucleic acid once inside a cell integrates in controlled manner in contrast to the integration of nucleic acids which are not virally transferred; nucleic acids transferred by other means such as calcium phosphate-DNA co-precipitation are subject to rearrangement and degradation.

The most commonly used recombinant retroviral vectors are derived from the amphotropic Moloney murine leukemia virus (MoMLV) [Miller and Baltimore (1986) *Mol. Cell. Biol.* 6:2895]. The MoMLV system has several advantages: 1) this specific retrovirus can infect many different cell types, 2) established packaging cell lines are available for the production of recombinant MoMLV viral particles and 3) the transferred genes are permanently integrated into the target cell chromosome. The established MoMLV vector systems comprise a DNA vector containing a small portion of the retroviral sequence (the viral long terminal repeat or "LTR" and the packaging or "psi" signal) and a packaging cell line. The gene to be transferred is inserted into the DNA vector. The viral sequences present on the DNA vector provide the signals necessary for the insertion or packaging of the vector RNA into the viral particle and for the expression of the inserted gene. The packaging cell line provides the viral proteins required for particle assembly [Markowitz *et al.* (1988) *J. Virol.* 62:1120].

Despite these advantages, existing retroviral vectors based upon MoMLV are limited by several intrinsic problems: 1) they do not infect non-dividing cells [Miller *et al.*, (1990) *Mol. Cell. Biol.* 10:4239], 2) they produce low titers of the recombinant virus [Miller and Rosman (1989) *BioTechniques* 7: 980 and Miller (1992) *Nature* 357: 455] and 3) they infect certain cell types (*e.g.*, human lymphocytes) with low efficiency [Adams *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:8981]. The low titers associated with MoMLV-based vectors has been attributed, at least in part, to the instability of the virus-encoded envelope protein. Concentration of retrovirus stocks by physical means (*e.g.*, ultracentrifugation and ultrafiltration) leads to a severe loss of infectious virus.

The low titer and inefficient infection of certain cell types by MoMLV-based vectors has been overcome by the use of pseudotyped retroviral vectors which contain the G protein of VSV as the membrane associated protein. Unlike retroviral envelope proteins which bind

to a specific cell surface protein receptor to gain entry into a cell, the VSV G protein interacts with a phospholipid component of the plasma membrane [Mastromarino *et al.* (1977) J. Gen. Virol. 68:2359]. Because entry of VSV into a cell is not dependent upon the presence of specific protein receptors, VSV has an extremely broad host range. Pseudotyped retroviral  
5 vectors bearing the VSV G protein have an altered host range characteristic of VSV (*i.e.*, they can infect almost all species of vertebrate, invertebrate and insect cells). Importantly, VSV G-pseudotyped retroviral vectors can be concentrated 2000-fold or more by ultracentrifugation without significant loss of infectivity [Burns *et al.* (1993) Proc. Natl. Acad. Sci. USA 90:8033].

10 The VSV G protein has also been used to pseudotype retroviral vectors based upon the human immunodeficiency virus (HIV) [Naldini *et al.* (1996) Science 272:263]. Thus, the VSV G protein may be used to generate a variety of pseudotyped retroviral vectors and is not limited to vectors based on MoMLV.

The present invention is not limited to the use of the VSV G protein when a viral G  
15 protein is employed as the heterologous membrane-associated protein within a viral particle. The G proteins of viruses in the Vesiculovirus genera other than VSV, such as the Piry and Chandipura viruses, that are highly homologous to the VSV G protein and, like the VSV G protein, contain covalently linked palmitic acid [Brun *et al.* (1995) Interviol. 38:274 and Masters *et al.* (1990) Virol. 171:285]; thus, the G protein of the Piry and Chandipura viruses  
20 can be used in place of the VSV G protein for the pseudotyping of viral particles. In addition, the VSV G proteins of viruses within the Lyssa virus genera such as Rabies and Mokola viruses show a high degree of conservation (amino acid sequence as well as functional conservation) with the VSV G proteins. For example, the Mokola virus G protein has been shown to function in a manner similar to the VSV G protein (*i.e.*, to mediate  
25 membrane fusion) and therefore may be used in place of the VSV G protein for the pseudotyping of viral particles [Mebatsion *et al.* (1995) J. Virol. 69:1444]. The nucleotide sequence encoding the Piry G protein is provided in SEQ ID NO:5 and the amino acid sequence of the Piry G protein is provided in SEQ ID NO:6. The nucleotide sequence encoding the Chandipura G protein is provided in SEQ ID NO:7 and the amino acid sequence  
30 of the Chandipura G protein is provided in SEQ ID NO:8. The nucleotide sequence encoding the Mokola G protein is provided in SEQ ID NO:9 and the amino acid sequence of the Mokola G protein is provided in SEQ ID NO:10. Viral particles may be pseudotyped using either the Piry, Chandipura or Mokola G protein as described in Example 2 with the

exception that a plasmid containing sequences encoding either the Piry, Chandipura or Mokola G protein under the transcriptional control of a suitable promoter element [*e.g.*, the CMV intermediate-early promoter; numerous expression vectors containing the CMV IE promoter are available, such as the pcDNA3.1 vectors (Invitrogen)] is used in place of pHCMV-G. Sequences encoding other G proteins derived from other members of the Rhabdoviridae family may be used; sequences encoding numerous rhabdoviral G proteins are available from the GenBank database.

## II. Integration of Retroviral DNA

The majority of retroviruses can transfer or integrate a double-stranded linear form of the virus (the provirus) into the genome of the recipient cell only if the recipient cell is cycling (*i.e.*, dividing) at the time of infection. Retroviruses which have been shown to infect dividing cells exclusively, or more efficiently, include MLV, spleen necrosis virus, Rous sarcoma virus and human immunodeficiency virus (HIV; while HIV infects dividing cells more efficiently, HIV can infect non-dividing cells).

It has been shown that the integration of MLV virus DNA depends upon the host cell's progression through mitosis and it has been postulated that the dependence upon mitosis reflects a requirement for the breakdown of the nuclear envelope in order for the viral integration complex to gain entry into the nucleus [Roe *et al.* (1993) EMBO J. 12:2099].

However, as integration does not occur in cells arrested in metaphase, the breakdown of the nuclear envelope alone may not be sufficient to permit viral integration; there may be additional requirements such as the state of condensation of the genomic DNA (Roe *et al.*, *supra*).

## III. Introduction of Retroviral Vectors Into Gametes Before the Last Meiotic Division

The nuclear envelope of a cell breaks down during meiosis as well as during mitosis. Meiosis occurs only during the final stages of gametogenesis. The methods of the present invention exploit the breakdown of the nuclear envelope during meiosis to permit the integration of recombinant retroviral DNA and permit for the first time the use of unfertilized oocytes (*i.e.*, pre-fertilization and pre-maturation oocytes) as the recipient cell for retroviral gene transfer for the production of transgenic animals. Because infection of unfertilized



oocytes permits the integration of the recombinant provirus prior to the division of the one cell embryo, all cells in the embryo will contain the proviral sequences.

Oocytes which have not undergone the final stages of gametogenesis are infected with the retroviral vector. The injected oocytes are then permitted to complete maturation with the accompanying meiotic divisions. The breakdown of the nuclear envelope during meiosis permits the integration of the proviral form of the retrovirus vector into the genome of the oocyte. When pre-maturation oocytes are used, the injected oocytes are then cultured *in vitro* under conditions which permit maturation of the oocyte prior to fertilization *in vitro*. Conditions for the maturation of oocytes from a number of mammalian species (*e.g.*, bovine, ovine, porcine, murine, caprine) are well known to the art. In general, the base medium used herein for the *in vitro* maturation of bovine oocytes, TC-M199 medium, may be used for the *in vitro* maturation of other mammalian oocytes. TC-M199 medium is supplemented with hormones (*e.g.*, luteinizing hormone and estradiol) from the appropriate mammalian species. The amount of time a pre-maturation oocyte must be exposed to maturation medium to permit maturation varies between mammalian species as is known to the art. For example, an exposure of about 24 hours is sufficient to permit maturation of bovine oocytes while porcine oocytes require about 44-48 hours.

Oocytes may be matured *in vivo* and employed in place of oocytes matured *in vitro* in the practice of the present invention. For example, when porcine oocytes are to be employed in the methods of the present invention, matured pre-fertilization oocytes may be harvested directly from pigs that are induced to superovulate as is known to the art. Briefly, on day 15 or 16 of estrus the female pig(s) is injected with about 1000 units of pregnant mare's serum (PMS; available from Sigma and Calbiochem). Approximately 48 hours later, the pig(s) is injected with about 1000 units of human chorionic gonadotropin (hCG; Sigma) and 24-48 hours later matured oocytes are collected from oviduct. These *in vivo* matured pre-fertilization oocytes are then injected with the desired retroviral preparation as described herein. Methods for the superovulation and collection of *in vivo* matured (*i.e.*, oocytes at the metaphase 2 stage) oocytes are known for a variety of mammals [*e.g.*, for superovulation of mice, see Hogan *et al.* (1994), *supra* at pp. 130-133; for superovulation of pigs and *in vitro* fertilization of pig oocytes see Cheng, W. (1995) Doctoral Dissertation, Cambridge University, Cambridge, United Kingdom].

Retroviral vectors capable of infecting the desired species of non-human animal which can be grown and concentrated to very high titers (*e.g.*,  $\geq 1 \times 10^8$  cfu/ml) are preferentially

employed. The use of high titer virus stocks allows the introduction of a defined number of viral particles into the perivitelline space of each injected oocyte. The perivitelline space of most mammalian oocytes can accommodate about 10 picoliters of injected fluid (those in the art know that the volume that can be injected into the perivitelline space of a mammalian oocyte or zygote varies somewhat between species as the volume of an oocyte is smaller than that of a zygote and thus, oocytes can accommodate somewhat less than can zygotes).

The vector used may contain one or more genes encoding a protein of interest; alternatively, the vector may contain sequences which produce anti-sense RNA sequences or ribozymes. The infectious virus is microinjected into the perivitelline space of oocytes (including pre-maturation oocytes) or one cell stage zygotes. Microinjection into the perivitelline space is much less invasive than the microinjection of nucleic acid into the pronucleus of an embryo. Pronuclear injection requires the mechanical puncture of the plasma membrane of the embryo and results in lower embryo viability. In addition, a higher level of operator skill is required to perform pronuclear injection as compared to perivitelline injection. Visualization of the pronucleus is not required when the virus is injected into the perivitelline space (in contrast to injection into the pronucleus); therefore injection into the perivitelline space obviates the difficulties associated with visualization of pronuclei in species such as cattle, sheep and pigs.

The virus stock may be titered and diluted prior to microinjection into the perivitelline space so that the number of proviruses integrated in the resulting transgenic animal is controlled. The use of a viral stock (or dilution thereof) having a titer of  $1 \times 10^8$  cfu/ml allows the delivery of a single viral particle per oocyte. The use of pre-maturation oocytes or mature fertilized oocytes as the recipient of the virus minimizes the production of animals which are mosaic for the provirus as the virus integrates into the genome of the oocyte prior to the occurrence of cell cleavage.

In order to deliver, on average, a single infectious particle per oocyte, the micropipets used for the injection are calibrated as follows. Small volumes (e.g., about 5-10 pl) of the undiluted high titer viral stock (e.g., a titer of about  $1 \times 10^8$  cfu/ml) are delivered to the wells of a microtiter plate by pulsing the micromanipulator. The titer of virus delivered per a given number of pulses is determined by diluting the viral stock in each well and determining the titer using a suitable cell line (e.g., the 208F cell line) as described in Ex. 2. The number of pulses which deliver, on average, a volume of virus stock containing one infectious viral

particle (*i.e.*, gives a MOI of 1 when titered on 208F cells) are used for injection of the viral stock into the oocytes.

Prior to microinjection of the titered and diluted (if required) virus stock, the cumulus cell layer is opened to provide access to the perivitelline space. The cumulus cell layer need  
5 not be completely removed from the oocyte and indeed for certain species of animals (*e.g.*, cows, sheep, pigs, mice) a portion of the cumulus cell layer must remain in contact with the oocyte to permit proper development and fertilization post-injection. Injection of viral particles into the perivitelline space allows the vector RNA (*i.e.*, the viral genome) to enter the cell through the plasma membrane thereby allowing proper reverse transcription of the  
10 viral RNA.

#### IV. Detection of the Retrovirus Following Injection Into Oocytes or Embryos

The presence of the retroviral genome in cells (*e.g.*, oocytes or embryos) infected with pseudotyped retrovirus may be detected using a variety of means. The expression of the gene  
15 product(s) encoded by the retrovirus may be detected by detection of mRNA corresponding to the vector-encoded gene products using techniques well known to the art (*e.g.*, Northern blot, dot blot, *in situ* hybridization and RT-PCR analysis). Direct detection of the vector-encoded gene product(s) is employed when the gene product is a protein which either has an enzymatic activity (*e.g.*,  $\beta$ -galactosidase) or when an antibody capable of reacting with the  
20 vector-encoded protein is available.

Alternatively, the presence of the integrated viral genome may be detected using Southern blot or PCR analysis. For example, the presence of the LZRNL or LSRNL genomes may be detected following infection of oocytes or embryos using PCR as follows. Genomic DNA is extracted from the infected oocytes or embryos (the DNA may be extracted  
25 from the whole embryo or alternatively various tissues of the embryo may be examined) using techniques well known to the art. The LZRNL and LSRNL viruses contain the *neo* gene and the following primer pair can be used to amplify a 349-bp segment of the *neo* gene: upstream primer: 5'-GCATTGCATCAGCCATGATG-3' (SEQ ID NO:1) and downstream primer: 5'-GATGGATTGCACGCAGGTTC-3' (SEQ ID NO:2). The PCR is carried out  
30 using well known techniques [*e.g.*, using a GeneAmp kit according to the manufacturer's instructions (Perkin-Elmer)]. The DNA present in the reaction is denatured by incubation at 94°C for 3 min followed by 40 cycles of 94°C for 1 min, 60°C for 40 sec and 72°C for 40 sec followed by a final extension at 72°C for 5 min. The PCR products may be analyzed by

electrophoresis of 10 to 20% of the total reaction on a 2% agarose gel; the 349-bp product may be visualized by staining of the gel with ethidium bromide and exposure of the stained gel to UV light. If the expected PCR product cannot be detected visually, the DNA can be transferred to a solid support (e.g., a nylon membrane) and hybridized with a <sup>32</sup>P-labeled *neo* probe.

Southern blot analysis of genomic DNA extracted from infected oocytes and/or the resulting embryos, offspring and tissues derived therefrom is employed when information concerning the integration of the viral DNA into the host genome is desired. To examine the number of integration sites present in the host genome, the extracted genomic DNA is typically digested with a restriction enzyme which cuts at least once within the vector sequences. If the enzyme chosen cuts twice within the vector sequences, a band of known (i.e., predictable) size is generated in addition to two fragments of novel length which can be detected using appropriate probes.

## EXPERIMENTAL

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

In the experimental disclosure which follows, the following abbreviations apply: M (molar); mM (millimolar);  $\mu$ M (micromolar); nM (nanomolar); mol (moles); mmol (millimoles);  $\mu$ mol (micromoles); nmol (nanomoles); gm (grams); mg (milligrams);  $\mu$ g (micrograms); pg (picograms); L (liters); ml (milliliters);  $\mu$ l (microliters); cm (centimeters); mm (millimeters);  $\mu$ m (micrometers); nm (nanometers); °C (degrees Centigrade); AMP (adenosine 5'-monophosphate); BSA (bovine serum albumin); cDNA (copy or complimentary DNA); CS (calf serum); DNA (deoxyribonucleic acid); ssDNA (single stranded DNA); dsDNA (double stranded DNA); dNTP (deoxyribonucleotide triphosphate); LH (luteinizing hormone); NIH (National Institutes of Health, Bethesda, MD); RNA (ribonucleic acid); PBS (phosphate buffered saline); g (gravity); OD (optical density); HEPES (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]); HBS (HEPES buffered saline); PBS (phosphate buffered saline); SDS (sodium dodecylsulfate); Tris-HCl (tris[Hydroxymethyl]aminomethane-hydrochloride); Klenow (DNA polymerase I large (Klenow) fragment); rpm (revolutions per minute); EGTA (ethylene glycol-bis( $\beta$ -aminoethyl ether) N, N, N', N'-tetraacetic acid); EDTA (ethylenediaminetetracetic acid); bla ( $\beta$ -lactamase or ampicillin-resistance gene); ORI (plasmid origin of replication); lacI (lac repressor); X-gal

(5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside); ATCC (American Type Culture Collection, Rockville, MD); GIBCO/BRL (GIBCO/BRL, Grand Island, NY); Perkin-Elmer (Perkin-Elmer, Norwalk, CT); and Sigam (Sigma Chemical Company, St. Louis, MO).

5

### EXAMPLE 1

#### Generation of Cell Lines Stably Expressing the MoMLV gag and pol Proteins

The expression of the fusogenic VSV G protein on the surface of cells results in  
10 syncytium formation and cell death. Therefore, in order to produce retroviral particles  
containing the VSV G protein as the membrane-associated protein a three step approach was  
taken. First, stable cell lines expressing the gag and pol proteins from MoMLV at high levels  
were generated (*e.g.*, 293GP cells; Example 1). These stable cell lines were then infected  
using the desired retroviral vector which is derived from an amphotrophic packaging cell  
15 (*e.g.*, PA317 cells transfected with the desired retroviral vector; Example 2a). The infected  
stable cell line which expresses the gag and pol proteins produces noninfectious viral particles  
lacking a membrane-associated protein (*e.g.*, a envelope protein). Third, these infected cell  
lines are then transiently transfected with a plasmid capable of directing the high level  
expression of the VSV G protein (Example 2b). The transiently transfected cells produce  
20 VSV G-pseudotyped retroviral vectors which can be collected from the cells over a period of  
3 to 4 days before the producing cells die as a result of syncytium formation.

The first step in the production of VSV G-pseudotyped retroviral vectors, the  
generation of stable cell lines expressing the MoMLV gag and pol proteins is described  
below.

25 The human adenovirus 5-transformed embryonal kidney cell line 293 (ATCC CRL  
1573) was cotransfected with the pCMVgag-pol and pFR400 plasmids using a ratio of 10:1  
(pCMVgag-pol and pFR400). pCMV gag-pol contains the MoMLV gag and pol genes under  
the control of the CMV promoter (pCMV gag-pol is available from the ATCC). pFR400  
encodes a mutant dihydrofolate reductase which has a reduced affinity for methotrexate  
30 [Simonsen *et al.*, Proc. Natl. Acad. Sci. 80:2495 (1983)].

The plasmid DNA was introduced into the 293 cells using calcium phosphate co-  
precipitation [Graham and Van der Eb, Virol. 52:456 (1973)]. Approximately  $5 \times 10^5$  293  
cells were plated into a 100 mm tissue culture plate the day before the DNA co-precipitate

was added. A total of 20 µg of plasmid DNA (18 µg pCMV gag-pol and 2 µg pFR400) was added as a calcium-DNA co-precipitate to each 100 mm plate. Stable transformants were selected by growth in DMEM-high glucose medium containing 10% FCS, 0.5 µM methotrexate and 5 µM dipyridimole (selective medium). Colonies which grew in the selective medium were screened for extracellular reverse transcriptase activity [Goff *et al.*, J. Virol. 38:239 (1981)] and intracellular p30<sup>gag</sup> expression. p30<sup>gag</sup> expression was determined by Western blotting using a goat-anti p30 antibody (NCI antiserum 77S000087). A clone which exhibited stable expression of the retroviral genes in the absence of continued methotrexate selection was selected. This clone was named 293GP (293 gag-pol). The 293GP cell line, a derivative of the human Ad-5-transformed embryonal kidney cell line 293, was grown in DMEM-high glucose medium containing 10% FCS. The 293GP cell line is commercially available from Viagen, Inc., San Diego, CA.

## EXAMPLE 2

### Preparation of Pseudotyped Retroviral Vectors Bearing the G Glycoprotein of VSV

In order to produce VSV G protein pseudotyped retrovirus the following steps were taken. First, the 293GP cell line was infected with virus derived from the amphotrophic packaging cell line PA317. The infected cells packaged the retroviral RNA into viral particles which lack a membrane-associated protein (because the 293GP cell line lacks an *env* gene or other gene encoding a membrane-associated protein). The infected 293GP cells were then transiently transfected with a plasmid encoding the VSV G protein to produce pseudotyped viral particles bearing the VSV G protein.

#### a) Cell Lines and Plasmids

The amphotrophic packaging cell line, PA317 (ATCC CRL 9078) was grown in DMEM-high glucose medium containing 10% FCS. The 293GP cell line was grown in DMEM-high glucose medium containing 10% FCS. The titer of the pseudo-typed virus may be determined using either 208F cells [Quade (1979) Virol. 98:461] or NIH/3T3 cells (ATCC CRL 1658); 208F and NIH/3T3 cells are grown in DMEM-high glucose medium containing 10% CS.

The plasmid pLZRNL [Xu *et al.* (1989) Virol. 171:331] contains the gene encoding *E. coli*  $\beta$ -galactosidase (LacZ) under the transcriptional control of the LTR of the Moloney murine sarcoma virus (MSV) followed by the gene encoding neomycin phosphotransferase (*Neo*) under the transcriptional control of the Rous sarcoma virus (RSV) promoter. The  
5 plasmid pLSRNL contains the gene encoding the hepatitis B surface antigen gene (HBsAg) under the transcriptional control of the MSV LTR followed by the *Neo* gene under the control of the RSV promoter (U.S. Patent No. 5,512,421, the disclosure of which is herein incorporated by reference). The plasmid pHCMV-G contains the VSV G gene under the transcriptional control of the human cytomegalovirus intermediate-early promoter [Yee *et al.*  
10 (1994) Meth. Cell Biol. 43:99].

**b) Production and Titering of Pseudotyped LZRNL Virus**

pLZRNL DNA was transfected into the amphotropic packaging line PA317 to produced LZRNL virus. The resulting LZRNL virus was then used to infect 293GP cells to  
15 produce pseudotyped LZRNL virus bearing the VSV G protein (following transient transfection of the infected 293GP cells with a plasmid encoding the VSV G protein). The procedure for producing pseudotyped LZRNL virus was carried out as described [Yee *et al.* (1994) Meth. Cell Biol. 43:99].

Briefly, on day 1, approximately  $5 \times 10^5$  PA317 cells were placed in a 100 mm tissue  
20 culture plate. On the following day (day 2), the PA317 cells were transfected with 20  $\mu$ g of pLZRNL plasmid DNA (plasmid DNA was purified using CsCl gradients) using the standard calcium phosphate co-precipitation procedure [Graham and Van der Eb (1973) Virol. 52:456]. A range of 10 to 40  $\mu$ g of plasmid DNA may be used. Because 293GP cells may take more than 24 hours to attach firmly to tissue culture plates, the 293GP cells may be placed in  
25 100 mm plates 48 hours prior to transfection. The transfected PA317 cells provide amphotropic LZRNL virus.

On day 3, approximately  $1 \times 10^5$  293GP cells were placed in a 100 mm tissue culture plate 24 hours prior to the harvest of the amphotropic virus from the transfected PA317 cells. On day 4, culture medium was harvested from the transfected PA317 cells 48 hours after the  
30 application of the pLZRNL DNA. The culture medium was filtered through a 0.45  $\mu$ m filter and polybrene was added to a final concentration of 8  $\mu$ g/ml. A stock solution of polybrene was prepared by dissolving 0.4 gm hexadimethrine bromide (polybrene; Sigma) in 100 ml sterile water; the stock solution was stored at 4°C. The culture medium containing LZRNL

virus (containing polybrene) was used to infect the 293GP cells as follows. The culture medium was removed from the 293GP cells and was replaced with the LZRNL virus containing culture medium. The virus containing medium was allowed to remain on the 293GP cells for 16 hours. Following the 16 hour infection period (on day 5), the medium was removed from the 293GP cells and was replaced with fresh medium containing 400  $\mu\text{g/ml}$  G418 (GIBCO/BRL). The medium was changed every 3 days until G418-resistant colonies appeared two weeks later. Care was taken not to disturb the G418-resistant colonies when the medium was changed as 293GP cells attach rather loosely to tissue culture plates.

The G418-resistant 293 colonies were picked using an automatic pipettor and transferred directly into 24-well plates (*i.e.*, the colonies were not removed from the plates using trypsin). The G418-resistant 293 colonies (as termed "293GP/LZRNL" cells) were screened for the expression of the *LacZ* gene in order to identify clones which produce high titers of pseudotyped LZRNL virus. Clones in 24-well plates were transferred to 100 mm tissue culture plates and allowed to grow to confluency. Protein extracts are prepared from the confluent plates by washing the cells once with 10 ml PBS (137 mM NaCl, 2.6 mM KCl, 8.1 mM  $\text{Na}_2\text{HPO}_4$ , 1.5 mM  $\text{KH}_2\text{PO}_4$ ). Two ml of 250 mM Tris-HCl, pH 7.8 was added and the cells were scrapped off the plate using a rubber policeman. The cells were then collected by centrifugation at room temperature and resuspended in 100  $\mu\text{l}$  250 mM Tris-HCl, pH 7.8. The cells were subjected to four rapid freeze/thaw cycles followed by centrifugation at room temperature to remove cell debris. The  $\beta$ -galactosidase activity present in the resulting protein extracts was determined as follows. Five microliters of protein extract was mixed with 500  $\mu\text{l}$   $\beta$ -gal buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM  $\text{MgCl}_2$ ) containing 0.75 ONPG (Sigma). The mixtures were incubated at 37°C until a yellow color appeared. The reactions were stopped by the addition of 500  $\mu\text{l}$  10 mM EDTA and the optical density of the reactions was determined at 420 nm.

The 293GP/LZRNL clone which generated the highest amount of  $\beta$ -galactosidase activity was then expanded and used subsequently for the production of pseudotyped LZRNL virus as follows. Approximately  $1 \times 10^6$  293GP/LZRNL cells were placed into a 100 mm tissue culture plate. Twenty-four hours later, the cells were transfected with 20  $\mu\text{g}$  of pHCMV-G plasmid DNA using calcium phosphate co-precipitation. Six to eight hours after the calcium-DNA precipitate was applied to the cells, the DNA solution was replaced with fresh culture medium (lacking G418). Longer transfection times (overnight) have been found



to result in the detachment of the majority of the 293GP/LZRNL cells from the plate and are therefore avoided. The transfected 293GP/LZRNL cells produce pseudotyped LZRNL virus.

The pseudotyped LZRNL virus generated from the transfected 293GP/LZRNL cells can be collected at least once a day between 24 and 96 hr after transfection. The highest virus titer was generated approximately 48 to 72 hr after initial pHCMV-G transfection. While syncytium formation became visible about 48 hr after transfection in the majority of the transfected cells, the cells continued to generate pseudotyped virus for at least an additional 48 hr as long as the cells remained attached to the tissue culture plate. The collected culture medium containing the VSV G-pseudotyped LZRNL virus was pooled, filtered through a 0.45  $\mu$ m filter and stored at -70°C.

The titer of the VSV G-pseudotyped LZRNL virus was then determined as follows.  $5 \times 10^5$  rat 208F fibroblasts or NIH 3T3 cells were plated in a 100 mm culture plate. Twenty-four hours after plating, the cells were infected with serial dilutions of the LZRNL virus-containing culture medium in the presence of 8  $\mu$ g/ml polybrene. Sixteen hours after infection with virus, the medium was replaced with fresh medium containing 400  $\mu$ g/ml G418 and selection was continued for 14 days until G418-resistant colonies became visible. Viral titers were typically about 0.5 to  $5.0 \times 10^6$  colony forming units (cfu)/ml. The titer of the virus stock could be concentrated to a titer of greater than  $10^9$  cfu/ml as described below.

### EXAMPLE 3

#### Concentration of Pseudotyped Retroviral Vectors

The VSV G-pseudotyped LZRNL virus was concentrated to a high titer by two cycles of ultracentrifugation. The frozen culture medium collected as described in Example 2 which contained pseudotyped LZRNL virus was thawed in a 37°C water bath and was then transferred to ultraclear centrifuge tubes (14 x 89 mm; Beckman, Palo Alto, CA) which had been previously sterilized by exposing the tubes to UV light in a laminar flow hood overnight. The virus was sedimented in a SW41 rotor (Beckman) at 50,000 x g (25,000 rpm) at 4°C for 90 min. The culture medium was then removed from the tubes in a laminar flow hood and the tubes were well drained. The virus pellet was resuspended to 0.5 to 1% of the original volume of culture medium in either TNE (50 mM Tris-HCl, pH 7.8; 130 mM NaCl; 1 mM EDTA) or 0.1X Hank's balanced salt solution [1X Hank's balanced salt solution contains 1.3 mM  $\text{CaCl}_2$ , 5 mM KCl, 0.3 mM  $\text{KH}_2\text{PO}_4$ , 0.5 mM  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 0.4 mM

MgSO<sub>4</sub>•7H<sub>2</sub>O, 138 mM NaCl, 4 mM NaHCO<sub>3</sub>, 0.3 mM NaH<sub>2</sub>PO<sub>4</sub>•H<sub>2</sub>O; 0.1X Hank's is made by mixing 1 parts 1X Hank's with 9 parts PBS]. The resuspended virus pellet was incubated overnight at 4°C without swirling. The virus pellet could be dispersed with gentle pipetting after the overnight incubation without significant loss of infectious virus. The titer of the virus stock was routinely increase 100- to 300-fold after one round of ultracentrifugation. The efficiency of recovery of infectious virus varied between 30 and 100%.

The virus stock was then subjected to low speed centrifugation in a microfuge for 5 min at 4°C to remove any visible cell debris or aggregated virions that were not resuspended under the above conditions (if the virus stock is not to be used for injection into oocytes or embryos, this centrifugation step may be omitted).

The virus stock was then subjected to another round of ultracentrifugation to concentrate the virus stock further. The resuspended virus from the first round of centrifugation was pooled and pelleted by a second round of ultracentrifugation which was performed as described above. Viral titers were increased approximately 2000-fold after the second round of ultracentrifugation (titers of the pseudotyped LZRN virus were typically greater than or equal to  $1 \times 10^9$  cfu/ml after the second round of ultracentrifugation).

The titers of the pre- and post-centrifugation fluids were determined by infection of 208F (NIH 3T3 or Mac-T cells can also be employed) followed by selection of G418-resistant colonies as described above in Example 2. The concentrated viral stock was stable (*i.e.*, did not lose infectivity) when stored at 4°C for several weeks.

#### EXAMPLE 4

##### Preparation of Pseudotyped Retrovirus For Infection of Oocytes and Embryos

The concentrated pseudotyped retrovirus were resuspended in 0.1X HBS (2.5 mM HEPES, pH 7.12, 14 mM NaCl, 75  $\mu$ M Na<sub>2</sub>HPO<sub>4</sub>•H<sub>2</sub>O) and 18  $\mu$ l aliquots were placed in 0.5 ml vials (Eppendorf) and stored at -80°C until used. The titer of the concentrated vector was determined by diluting 1 $\mu$ l of the concentrated virus 10<sup>-7</sup>- or 10<sup>-8</sup>-fold with 0.1X HBS. The diluted virus solution was then used to infect 208F and Mac-T cells and viral titers were determined as described in Example 2.

Prior to infection of oocytes or embryos (by microinjection), 1  $\mu$ l of polybrene [25 ng/ $\mu$ l; the working solution of polybrene was generated by diluting a stock solution having a concentration of 1 mg/ml (in sterile H<sub>2</sub>O) in 0.1 HBS, pH 7.12] was mixed with 4  $\mu$ l of

concentrated virus to yield a solution containing  $10^3$ - $10^4$  cfu/ $\mu$ l and 8  $\mu$ g/ml polybrene. This solution was loaded into the injection needle (tip having an internal diameter of approximately 2-4  $\mu$ m) for injection into the perivitelline space of gametes (pre-maturation oocytes, matured oocytes) or one cell stage zygotes (early stage embryo). An Eppendorf Transjector 5246 was used for all microinjections.

## EXAMPLE 5

### Preparation and Microinjection of Gametes and Zygotes

Gametes (pre-maturation and pre-fertilization oocytes) and zygotes (fertilized oocytes) were prepared and microinjected with retroviral stocks as described below.

#### a) Solutions

Tyrodes-Lactate with HEPES (TL-HEPES): 114 mM NaCl, 3.2 mM KCl, 2.0 mM  $\text{NaHCO}_3$ , 0.4 mM  $\text{Na}_2\text{H}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ , 10 mM Na-lactate, 2 mM  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 0.5 mM  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 10 mM HEPES, 100 IU/ml penicillin, 50  $\mu$ g/ml phenol red, 1 mg/ml BSA fraction V, 0.2 mM pyruvate and 25  $\mu$ g/ml gentamycin.

Maturation Medium: TC-199 medium (GIBCO) containing 10% FCS, 0.2 mM pyruvate, 5  $\mu$ g/ml NIH o-LH (NIH), 25  $\mu$ g/ml gentamycin and 1  $\mu$ g/ml estradiol-17 $\beta$ .

Sperm-Tyrodes-Lactate (Sperm-TL): 100 mM NaCl, 3.2 mM KCl, 25 mM  $\text{NaHCO}_3$ , 0.29 mM  $\text{Na}_2\text{H}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ , 21.6 mM Na-lactate, 2.1 mM  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 0.4 mM  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 10 mM HEPES, 50  $\mu$ g/ml phenol red, 6 mg/ml BSA fraction V, 1.0 mM pyruvate and 25  $\mu$ g/ml gentamycin.

Fertilization Medium: 114 mM NaCl, 3.2 mM KCl, 25 mM  $\text{NaHCO}_3$ , 0.4 mM  $\text{Na}_2\text{H}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ , 10 mM Na-lactate, 2 mM  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 0.5 mM  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ , 100 IU/ml penicillin, 50  $\mu$ g/ml phenol red, 6 mg/ml BSA fatty acid free, 0.2 mM pyruvate and 25  $\mu$ g/ml gentamycin.

PHE: 1 mM hypotaurine, 2 mM penicillamine and 250  $\mu$ M epinephrine.

Embryo Incubation + Amino Acids (EIAA): 114  $\mu$ M NaCl, 3.2  $\mu$ M KCl, 25  $\mu$ M  $\text{NaHCO}_3$ , 1.6  $\mu$ g/ml L(+)-lactate, 10.7  $\mu$ g/ml L-glutamine, 300  $\mu$ g/ml BSA fatty acid free, 0.275  $\mu$ g/ml pyruvate, 25  $\mu$ g/ml gentamycin, 10  $\mu$ l of 100X MEM amino acids stock (M7145, Sigma) per ml and 20  $\mu$ l of 50X BME amino acids stock (B6766, Sigma) per ml.

0.1X HBS: 2.5 mM HEPES (pH 7.12), 14 mM NaCl and 75  $\mu$ M  $\text{Na}_2\text{HPO}_4 \cdot \text{H}_2\text{O}$ .

**b) Preparation, Injection, Maturation and Fertilization of Pre-Maturation Oocytes**

Oocytes were aspirated from small antral follicles on ovaries from dairy cattle obtained from a slaughterhouse. Freshly aspirated oocytes at the germinal vesicle (GV) stage, meiosis arrested, with the cumulus mass attached were selected (*i.e.*, pre-maturation oocytes). The oocytes were then washed twice in freshly prepared TL-HEPES and transferred into a 100  $\mu$ l drop of TL-HEPES for microinjection.

Concentrated retroviral particles (prepared as described in Example 3) were resuspended in 0.1X HBS, mixed with polybrene and loaded into the injection needle as described in Example 4. Approximately 10  $\mu$ l of the virus solution was then injected into the perivitelline space of pre-maturation oocytes.

Following injection, the pre-maturation oocytes were washed twice in fresh TL-HEPES and transferred into maturation medium (10 oocytes in 50  $\mu$ l). The pre-maturation oocytes were then incubated in Maturation Medium for 24 hours at 37°C which permits the oocytes to mature to the metaphase II stage. The matured oocytes were then washed twice in Sperm-TL and 10 oocytes were then transferred into 44  $\mu$ l of Fertilization Medium. The mature oocytes (10 oocytes/44  $\mu$ l Fertilization Medium) were then fertilized by the addition of 2  $\mu$ l of sperm at a concentration of  $2.5 \times 10^7$ /ml, 2  $\mu$ l of PHE and 2  $\mu$ l of heparin (fertilization mixture). Sperm was prepared by discontinuous percoll gradient separation of frozen-thawed semen as described [Kim *et al.* (1993) Mol. Reprod. Develop. 35:105]. Briefly, percoll gradients were formed by placing 2 ml of each of 90% and 45% percoll in a 15 ml conical tube. Frozen-thawed semen was layered on top of the gradient and the tubes were centrifuged for 10 minutes at 700xg. Motile sperm were collected from the bottom of the tube.

The oocytes were incubated for 16 to 24 hours at 37°C in the fertilization mixture. Following fertilization, the cumulus cells were removed by vortexing the cells (one cell stage zygotes, Pronucleus Stage) for 3 minutes to produce "nude" oocytes. The nude oocytes were then washed twice in embryo culture medium (EIAA) and 20 to 25 zygotes were then cultured in 50  $\mu$ l drop of EIAA (without serum until Day 4 at which time the zygotes were placed in EIAA containing 10% serum) until the desired developmental stage was reached: approximately 48 hours or Day 2 (Day 0 is the day when the matured oocytes are co-cultured with sperm) for morula stage (8 cell stage) or Day 6-7 for blastocyst stage. Embryos at the morula stage were analyzed for expression of  $\beta$ -galactosidase as described in Example 6.

Embryos derived from injected pre-maturation oocytes were also analyzed for  $\beta$ -galactosidase expression at the 2 cell, 4 cell, and blastocyst stage and all developmental stages examined were positive.

5           c)       **Preparation, Injection and Fertilization of Pre-Fertilization Oocytes**

Pre-maturation oocytes were harvested, washed twice with TL-HEPES as described above. The oocytes were then cultured in Maturation Medium (10 oocytes per 50  $\mu$ l medium) for 16 to 20 hours to produce pre-fertilization oocytes (Metaphase II Stage). The pre-fertilization or matured oocytes were then vortexed for 3 minutes to remove the cumulus  
10 cells to produce nude oocytes. The nude oocytes were washed twice in TL-HEPES and then transferred into a 100  $\mu$ l drop of TL-HEPES for microinjection. Microinjection was conducted as described above.

Following microinjection, the pre-fertilization oocytes were washed twice with TL-HEPES and then placed in Maturation Medium until fertilization. Fertilization was conducted  
15 as described above. Following fertilization, the zygotes were then washed twice in EIAA and 20 to 25 zygotes were then cultured per 50  $\mu$ l drop of EIAA until the desired developmental stage was reached. The embryos were then examined for  $\beta$ -galactosidase expression (Ex. 6) or transferred to recipient cows (Ex. 7).

20           d)       **Preparation and Injection of One-Cell Stage Zygotes**

Matured oocytes (Metaphase II stage) were generated as described above. The matured oocytes were then co-cultured in the presence of sperm for 16 to 20 hours as described above to generate zygotes at the pronucleus stage. Zygotes at the pronucleus stage were vortexed for 3 minutes to remove the cumulus cell layer prior to microinjection.  
25 Microinjection of retrovirus was conducted as described above. Following microinjection, the zygotes were washed four times in EIAA and then placed in an EIAA culture drop (25 zygotes per 50  $\mu$ l drop of EIAA). The zygotes were cultured in EIAA (20 to 25 zygote per 50  $\mu$ l drop of EIAA) until the desired developmental stage was reached. The embryos were then examined for  $\beta$ -galactosidase expression (Ex. 6) or transferred to recipient cows (Ex. 7).

30

**EXAMPLE 6****Injection of Pseudotyped Retrovirus Into the Perivitelline Space of Maturing Bovine Oocytes  
Results in the Efficient Transfer of Vector Sequences**

Oocytes and one-cell zygotes which had been microinjected with pseudotyped LZRNL virus and cultured *in vitro* were examined for expression of vector sequences by staining for  $\beta$ -galactosidase activity when the embryos had reached the morula stage.  $\beta$ -galactosidase activity was examined as follows. Embryos were washed twice in PBS then fixed in 0.5% glutaraldehyde in PBS containing 2mM  $MgCl_2$  for 40 min. at 4 °C . The fixed embryos were then washed three times with PBS containing 2mM  $MgCl_2$  and then incubated at 37°C overnight in X-gal solution (20mM  $K_3Fe(CN)_6$ , 20mM  $K_4Fe(CN)_6 \cdot H_2O$ , 2 mM  $MgCl_2$  and 1 mg/ml X-gal). The presence of a blue precipitate indicates expression of  $\beta$ -galactosidase activity. The results are shown in Table 1 below.

**TABLE 1**

Stage at Injection	Stage at Analysis	% Positive For $\beta$ -galactosidase Expression
Pre-Fertilization Oocyte (injected 20-24 hrs after exposure to Maturation Medium)	Morula	47 (80/172) <sup>a</sup>
Pronuclei Stage (injected 18-20 hrs after exposure to sperm)	Morula	25 (20/80)
One-Cell Zygote	Morula	25 (20/80)

<sup>a</sup> Number positive/number injected.

From the results shown in Table 1, it is clear that infection of pre-fertilization oocytes and zygotes using the methods of the present invention results in the transfer and expression of retrovirally encoded nucleic acid. While not limiting the present invention to any particular theory, it is currently believed that only half of the daughter cells from an initial founder cell infected with a retrovirus will contain the provirus because the retroviral provirus integrates into post-replication host DNA [Hajihosseini et al. (1993) EMBO J. 12:4969]. Therefore, the finding that 47% of the injected pre-fertilization oocytes are positive for  $\beta$ -

galactosidase expression suggests that 100% of these injected oocytes were infected with the recombinant retrovirus. Therefore, the methods of the present invention provide an efficiency of generating transgenic embryos which is superior to existing methods.

5

### EXAMPLE 7

#### Generation of Transgenic Cows Containing Integrated Retroviral Nucleic Acid Sequences

10 Embryos derived from infected pre-fertilization oocytes and early zygotes were transferred into recipient cows which were allowed to progress to term as described below.

##### a) Treatment of Embryos Derived From Infected Oocytes and Zygotes

Pre-fertilization oocytes (infected about 17 hours after exposure to Maturation  
15 Medium) and early stage zygotes ( $\leq 8$  cell stage) were prepared and infected as described in Example 5 with the exceptions that 1) the VSV-G-pseudotyped virus used was the LSRNL virus which was prepared as described for the LZRNL virus in Ex. 2 and 2) at day 4 post-fertilization, embryos derived from injected pre-fertilization oocytes and zygotes were placed in freshly prepared EIAA medium containing 10% FCS and allowed to develop *in vitro* until  
20 transfer into recipient cows. Embryos at Day 7 were transferred into recipient females which were prepared as described below.

##### b) Preparation of Recipient Cows and Embryo Transfer

Recipients cows were synchronized by injecting 100  $\mu$ g of gonadotropin-releasing  
25 hormone (GnRH; Sanofi Winthrop Pharmaceutical Inc., New York, NY) (Day 0). Seven days later, the recipients were injected with 25 mg of PGF2 $\alpha$  (Upjohn Co., Kalamazoo, MI). Thirty to 48 hours after injection of PGF2 $\alpha$ , a second injection of 100  $\mu$ g of GnRH was given. Ovulation occurs about 24-32 hours post injection. Seven days after ovulation occurred, embryos derived from infected oocytes and zygotes (Day 7 embryos) were then  
30 transferred nonsurgically to the uteri the recipient cows. Two embryos were transferred into each recipient (it is expected that only one calf will be born from the transfer of two embryos into a single recipient).

A total of 20 embryos were transferred into recipients on three separate days. In the first transfer 8 embryos derived from infected pre-fertilization oocytes were transferred into 4 recipients; four calves were born to these recipients and all four were found to be positive for the presence of vector proviral DNA (*i.e.*, 100% were transgenic). In the second transfer 8 embryos derived from pre-fertilization oocytes were transferred into 4 recipients; 2 calves were born to these recipients and one of these animals was found to be transgenic (in the second transfer, one pregnancy was lost in the first month and another pregnancy comprising twins was lost in the eighth month; neither embryo from the 8 month pregnancy was transgenic). In the third transfer 4 embryos derived from infected zygotes (infected at the 4-8 cell stage) were transferred into 2 recipients; 3 calves were born to these recipients and none were transgenic.

The nine calves appeared healthy at birth and continue to appear healthy at the age of 6 months. Following the birth of offspring derived from the injected oocytes and zygotes, the offspring were examined by Southern blot and PCR analyses to determine whether they contained the retroviral transgenes and whether they exhibited somatic cell mosaicism. Skin tissue and white blood cells (buffy coat) was collected from the calves. Genomic DNA was extracted using standard techniques. Briefly, the tissue samples were digested with 50 µg/ml proteinase K (GIBCO) at 55°C. The samples were then extracted sequentially twice with an equal volume of phenol, once with phenol:chloroform (1:1) and once with chloroform. The DNA present in the aqueous layer was then precipitated by the addition of 2 volumes of isopropanol. The DNA was collected by centrifugation and the DNA pellet was resuspended in TE buffer (10mM Tris-Cl, 1 mM EDTA, pH 8.0) and the concentration was determined spectrophotometrically. The DNA was then analyzed by Southern blotting and PCR analysis. The results are shown in Figures 2 and 3.

Figure 2 shows an autoradiography of a Southern blot of genomic DNA isolated from the skin (Fig. 2A) and blood (Fig. 2B) of the six calves derived from either pre-fertilization oocytes infected with VSV G-pseudotyped LSRNL virus at about 17 hours after exposure to Maturation Medium (calves numbered 17, 18, 20 and 21) or one cell zygotes infected at about 12 hrs post-fertilization (calves numbered 15 and 16). The calf DNA was digested with *Hind*III which cuts the pLSRNL vector twice to generate a 1.6 kb fragment (Fig. 2C). *Hind*III-digested DNA from the blood (lane labelled \*12 derived from a random, nontransgenic calf), ovary and semen of nontransgenic cows (derived random adult females and males) were also included. Lanes labeled "3989 M and F" represent DNA derived from



two late term embryos that were born one month prematurely (these calves were generated from injected fertilized eggs and both are nontransgenic). Lanes labelled "LSRNL pDNA" contain *Hind*III-digested pLSRNL plasmid DNA and provide controls for the quantitation of the copy number of the integrated proviruses in the offspring (DNA equivalent to 5, 10 or 25 copies of LSRNL were applied in these lanes).

Approximately 10 µg of the *Hind*III-digested DNAs were electrophoresed on 0.8% agarose gels, and blotted onto a nylon membrane. The membrane was hybridized with a <sup>32</sup>P-labelled probe which hybridizes to the HBsAg gene present in the pLZRNL vector (Fig. 2C). The HBsAg probe was generated by PCR amplification of pLSRNL plasmid DNA using the upstream primer S-1 [5'-GGCTATCGCTGGATGTGTCT-3' (SEQ ID NO:3)] and the downstream primer S-3 [5'-ACTGAACAAATGGCACTAGT-3' (SEQ ID NO:4)]. The PCR-generated probe (334 bp) was labeled using a Rediprime kit (Amersham, Arlington Heights, IL) according to the manufacturer's instructions. The autoradiographs shown in Fig. 2 were generated by exposure of the blots to X-ray film for 3 weeks at -80°C.

The results shown in Figure 2 demonstrates that calves 16, 17, 18, 20 and 21 contained retroviral vector DNA in both the skin (Fig. 2A) and blood (Fig. 2B). As blood cells (buffy coat) are derived from the mesoderm and skin cells are derived from the ectoderm, these results show that the transgenic animals do not display somatic cell mosaicism. Southern blotting analysis has shown that the majority (*i.e.*, 7/9) of the transgenic calves contain a single copy of the proviral sequence; a few (*i.e.*, 2/9) animals appear to contain two copies of the integrated proviral sequence. These results further demonstrate that retroviral infection of both pre-fertilization oocytes and early stage zygotes was successful in integrating the viral sequences into the genome of the resulting transgenic animals.

In order to confirm the presence of integrated retroviral sequences in the genome of the transgenic animals' somatic cells, PCR analysis (Fig. 3) was performed using genomic DNA isolated from the five transgenic calves which were determined by Southern blot analysis to be transgenic for the retroviral sequences. Figure 3 shows the results of the PCR analysis following amplification of two different regions (*i.e.*, the *neo* gene and the *HBsAg* gene) of the LZRNL retroviral genome which was injected into the oocytes. Genomic DNA from the skin and blood of each of the five transgenic calves was amplified using the upstream and downstream primers (SEQ ID NOS:1 and 2 and NOS:3 and 4; described *supra*) for the *neo* (Fig. 3A) and *HBsAg* (Fig. 3B) genes, respectively. The PCRs were

conducted using the following thermocycling conditions: 94°C ( 4 min); [94°C (2 min); 50°C (2 min); 72°C (2 min)] <sup>30 cycles</sup>; 72°C (10 min). Amplification yielded the expected size of amplified sequence with the *neo* (349 bp) and *HBsAg* (334 bp) primers in both the blood and skin of each of the five transgenic calves. Genomic DNA isolated from the blood of non-transgenic calves as well as from semen and ovary of non-transgenic cattle were used as negative controls in the PCRs. pLSRNL DNA was used as the positive control.

These data demonstrate that the infection of pre-fertilization oocytes results in the efficient transfer of retroviral vector DNA (100% or 4 transgenic calves/4 calves born from embryos derived from infected pre-fertilization oocytes). In addition to providing a means for efficiently generating transgenic animals. The methods of the present invention provide a means for generating transgenic animals which do not display somatic cell mosaicism. Further, these methods permit the production of transgenic animals which contain a single copy of the transgene.

In order to confirm germ line transmission of the integrated viral sequences, the transgenic offspring are bred with non-transgenic cattle and the presence of the viral sequences (*i.e.*, the transgene) is determined using Southern blot analysis or PCR amplification as described above. Animals which are heterozygous or homozygous for the transgene are produced using methods well known to the art (*e.g.*, interbreeding of animals heterozygous for the transgene).

From the above it is clear that the invention provides improved methods and compositions for the production of transgenic non-human animals. The methods of the present invention provide for the production of transgenic non-human animals with improved efficiency and a reduced incidence of generating animals which are mosaic for the presence of the transgene.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Bremel, Robert D.  
Chan, Anthony W.S.  
Burns, Jane C.
- (ii) TITLE OF INVENTION: Methods For Creating Transgenic Animals
- (iii) NUMBER OF SEQUENCES: 10
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Medlen & Carroll, LLP
  - (B) STREET: 220 Montgomery Street, Suite 2200
  - (C) CITY: San Francisco
  - (D) STATE: California
  - (E) COUNTRY: United States of America
  - (F) ZIP: 94104
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Ingolia, Diane E.
  - (B) REGISTRATION NUMBER: 40,027
  - (C) REFERENCE/DOCKET NUMBER: WARF-02184
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (415) 705-8410
  - (B) TELEFAX: (415) 397-8338

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCATTGCATC AGCCATGATG

20

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
  - (A) DESCRIPTION: /desc = "DNA"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GATGGATTGC ACGCAGGTTC

20

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid  
 (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGCTATCGCT GGATGTGTCT

20

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid  
 (A) DESCRIPTION: /desc = "DNA"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ACTGAACAAA TGGCACTAGT

20

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1590 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid  
 (A) DESCRIPTION: /desc = "DNA"

- (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 1..1587

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG GAT CTC TTT CCC ATT TTG GTC GTG GTG CTC ATG ACA GAT ACT GTC	48
Met Asp Leu Phe Pro Ile Leu Val Val Val Leu Met Thr Asp Thr Val	
1 5 10 15	
TTA GGG AAG TTT CAA ATT GTC TTC CCG GAT CAG AAT GAA CTG GAG TGG	96
Leu Gly Lys Phe Gln Ile Val Phe Pro Asp Gln Asn Glu Leu Glu Trp	
20 25 30	
AGA CCA GTT GTG GGT GAC TCT CGG CAT TGC CCA CAG TCA TCA GAA ATG	144
Arg Pro Val Val Gly Asp Ser Arg His Cys Pro Gln Ser Ser Glu Met	
35 40 45	
CAA TTC GAT GGA AGC AGA TCC CAG ACC ATA CTG ACT GGG AAA GCT CCC	192
Gln Phe Asp Gly Ser Arg Ser Gln Thr Ile Leu Thr Gly Lys Ala Pro	
50 55 60	
GTG GGG ATC ACG CCC TCT AAA TCA GAT GGA TTT ATC TGC CAT GCC GCA	240
Val Gly Ile Thr Pro Ser Lys Ser Asp Gly Phe Ile Cys His Ala Ala	
65 70 75 80	
AAA TGG GTG ACA ACA TGT GAT TTC AGG TGG TAT GGG CCG AAA TAC ATC	288
Lys Trp Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Lys Tyr Ile	
85 90 95	

ACT CAT TCA ATA CAT CAT CTG AGA CCG ACA ACA TCA GAC TGT GAG ACA Thr His Ser Ile His His Leu Arg Pro Thr Thr Ser Asp Cys Glu Thr 100 105 110	336
GCT CTC CAA AGG TAT AAA GAT GGG AGC TTA ATC AAT CTT GGA TTC CCC Ala Leu Gln Arg Tyr Lys Asp Gly Ser Leu Ile Asn Leu Gly Phe Pro 115 120 125	384
CCA GAA TCC TGC GGT TAT GCA ACA GTC ACA GAT TCT GAG GCA ATG TTG Pro Glu Ser Cys Gly Tyr Ala Thr Val Thr Asp Ser Glu Ala Met Leu 130 135 140	432
GTC CAA GTG ACT CCC CAC CAC GTT GGG GTG GAT GAT TAT AGA GGT CAC Val Gln Val Thr Pro His His Val Gly Val Asp Asp Tyr Arg Gly His 145 150 155 160	480
TGG ATC GAC CCA CTA TTT CCA GGA GGA GAA TGC TCC ACC AAT TTT TGT Trp Ile Asp Pro Leu Phe Pro Gly Gly Glu Cys Ser Thr Asn Phe Cys 165 170 175	528
GAT ACA GTC CAC AAT TCA TCG GTG TGG ATC CCC AAG AGT CAA AAG ACT Asp Thr Val His Asn Ser Ser Val Trp Ile Pro Lys Ser Gln Lys Thr 180 185 190	576
GAC ATC TGT GCC CAG TCT TTC AAA AAT ATC AAG ATG ACC GCA TCT TAC Asp Ile Cys Ala Gln Ser Phe Lys Asn Ile Lys Met Thr Ala Ser Tyr 195 200 205	624
CCC TCA GAA GGA GCA TTG GTG AGT GAC AGA TTT GCC TTC CAC AGT GCA Pro Ser Glu Gly Ala Leu Val Ser Asp Arg Phe Ala Phe His Ser Ala 210 215 220	672
TAT CAT CCA AAT ATG CCG GGG TCA ACT GTT TGC ATA ATG GAC TTT TGC Tyr His Pro Asn Met Pro Gly Ser Thr Val Cys Ile Met Asp Phe Cys 225 230 235 240	720
GAA CAA AAG GGG TTG AGA TTC ACA AAT GGA GAG TGG ATG GGT CTC AAT Glu Gln Lys Gly Leu Arg Phe Thr Asn Gly Glu Trp Met Gly Leu Asn 245 250 255	768
GTG GAG CAA TCC ATC CGA GAG AAG AAG ATA AGT GCC ATC TTC CCA AAT Val Glu Gln Ser Ile Arg Glu Lys Lys Ile Ser Ala Ile Phe Pro Asn 260 265 270	816
TGT GTT GCA GGG ACT GAA ATC CGA GCC ACA CTA GAA TCA GAA GGG GCA Cys Val Ala Gly Thr Glu Ile Arg Ala Thr Leu Glu Ser Glu Gly Ala 275 280 285	864
AGA ACT TTG ACG TGG GAG ACT CAA AGA ATG CTA GAT TAC TCT TTG TGT Arg Thr Leu Thr Trp Glu Thr Gln Arg Met Leu Asp Tyr Ser Leu Cys 290 295 300	912
CAG AAC ACC TGG GAC AAA GTT TCC AGG AAA GAA CCT CTC AGT CCG CTT Gln Asn Thr Trp Asp Lys Val Ser Arg Lys Glu Pro Leu Ser Pro Leu 305 310 315 320	960
GAC TTG AGC TAT CTG TCA CCA AGG GCT CCA GGG AAA GGC ATG GCC TAT Asp Leu Ser Tyr Leu Ser Pro Arg Ala Pro Gly Lys Gly Met Ala Tyr 325 330 335	1008
ACC GTC ATA AAC GGA ACC CTG CAT TCG GCT CAT GCT AAA TAC ATT AGA Thr Val Ile Asn Gly Thr Leu His Ser Ala His Ala Lys Tyr Ile Arg 340 345 350	1056
ACC TGG ATT GAT TAT GGA GAA ATG AAG GAA ATT AAA GGT GGA CGT GGA Thr Trp Ile Asp Tyr Gly Glu Met Lys Glu Ile Lys Gly Gly Arg Gly 355 360 365	1104

GAA TAT TCC AAG GCT CCT GAG CTC CTC TGG TCC CAG TGG TTC GAT TTT Glu Tyr Ser Lys Ala Pro Glu Leu Leu Trp Ser Gln Trp Phe Asp Phe 370 375 380	1152
GGA CCG TTC AAA ATT GGA CCG AAT GGA CTC CTG CAC ACA GGG AAA ACC Gly Pro Phe Lys Ile Gly Pro Asn Gly Leu Leu His Thr Gly Lys Thr 385 390 395 400	1200
TTT AAA TTC CCT CTT TAT TTG ATC GGA GCA GGC ATA ATT GAC GAA GAT Phe Lys Phe Pro Leu Tyr Leu Ile Gly Ala Gly Ile Ile Asp Glu Asp 405 410 415	1248
CTG CAT GAA CTA GAT GAG GCT GCT CCC ATT GAT CAC CCA CAA ATG CCT Leu His Glu Leu Asp Glu Ala Ala Pro Ile Asp His Pro Gln Met Pro 420 425 430	1296
GAC GCG AAA AGC GTT CTT CCA GAA GAT GAA GAG ATA TTC TTC GGA GAC Asp Ala Lys Ser Val Leu Pro Glu Asp Glu Glu Ile Phe Phe Gly Asp 435 440 445	1344
ACA GGT GTA TCC AAA AAC CCT ATC GAG TTG ATT CAA GGA TGG TTC TCA Thr Gly Val Ser Lys Asn Pro Ile Glu Leu Ile Gln Gly Trp Phe Ser 450 455 460	1392
AAT TGG AGA GAG AGT GTA ATG GCA ATA GTC GGA ATT GTT CTA CTC ATC Asn Trp Arg Glu Ser Val Met Ala Ile Val Gly Ile Val Leu Leu Ile 465 470 475 480	1440
GTT GTG ACA TTT CTG GCG ATC AAG ACG GTC CGG GTG CTT AAT TGT CTC Val Val Thr Phe Leu Ala Ile Lys Thr Val Arg Val Leu Asn Cys Leu 485 490 495	1488
TGG AGA CCC AGA AAG AAA AGA ATC GTC AGA CAA GAA GTA GAT GTT GAA Trp Arg Pro Arg Lys Lys Arg Ile Val Arg Gln Glu Val Asp Val Glu 500 505 510	1536
TCC CGA CTA AAC CAT TTT GAG ATG AGA GGC TTT CCT GAA TAT GTT AAG Ser Arg Leu Asn His Phe Glu Met Arg Gly Phe Pro Glu Tyr Val Lys 515 520 525	1584
AGA TAA Arg	1590

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 529 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Asp Leu Phe Pro Ile Leu Val Val Val Leu Met Thr Asp Thr Val 1 5 10 15
Leu Gly Lys Phe Gln Ile Val Phe Pro Asp Gln Asn Glu Leu Glu Trp 20 25 30
Arg Pro Val Val Gly Asp Ser Arg His Cys Pro Gln Ser Ser Glu Met 35 40 45
Gln Phe Asp Gly Ser Arg Ser Gln Thr Ile Leu Thr Gly Lys Ala Pro 50 55 60
Val Gly Ile Thr Pro Ser Lys Ser Asp Gly Phe Ile Cys His Ala Ala 65 70 75 80

- 37 -

Thr Gly Val Ser Lys Asn Pro Ile Glu Leu Ile Gln Gly Trp Phe Ser  
 450 455 460

Asn Trp Arg Glu Ser Val Met Ala Ile Val Gly Ile Val Leu Leu Ile  
 465 470 475 480

Val Val Thr Phe Leu Ala Ile Lys Thr Val Arg Val Leu Asn Cys Leu  
 485 490 495

Trp Arg Pro Arg Lys Lys Arg Ile Val Arg Gln Glu Val Asp Val Glu  
 500 505 510

Ser Arg Leu Asn His Phe Glu Met Arg Gly Phe Pro Glu Tyr Val Lys  
 515 520 525

Arg

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1590 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "DNA"

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1587

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATG GAT CTC TTT CCC ATT TTG GTC GTG GTG CTC ATG ACA GAT ACT GTC	48
Met Asp Leu Phe Pro Ile Leu Val Val Val Leu Met Thr Asp Thr Val	
1 5 10 15	
TTA GGG AAG TTT CAA ATT GTC TTC CCG GAT CAG AAT GAA CTG GAG TGG	96
Leu Gly Lys Phe Gln Ile Val Phe Pro Asp Gln Asn Glu Leu Glu Trp	
20 25 30	
AGA CCA GTT GTG GGT GAC TCT CGG CAT TGC CCA CAG TCA TCA GAA ATG	144
Arg Pro Val Val Gly Asp Ser Arg His Cys Pro Gln Ser Ser Glu Met	
35 40 45	
CAA TTC GAT GGA AGC AGA TCC CAG ACC ATA CTG ACT GGG AAA GCT CCC	192
Gln Phe Asp Gly Ser Arg Ser Gln Thr Ile Leu Thr Gly Lys Ala Pro	
50 55 60	
GTG GGG ATC ACG CCC TCT AAA TCA GAT GGA TTT ATC TGC CAT GCC GCA	240
Val Gly Ile Thr Pro Ser Lys Ser Asp Gly Phe Ile Cys His Ala Ala	
65 70 75 80	
AAA TGG GTG ACA ACA TGT GAT TTC AGG TGG TAT GGG CCG AAA TAC ATC	288
Lys Trp Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Lys Tyr Ile	
85 90 95	
ACT CAT TCA ATA CAT CAT CTG AGA CCG ACA ACA TCA GAC TGT GAG ACA	336
Thr His Ser Ile His His Leu Arg Pro Thr Thr Ser Asp Cys Glu Thr	
100 105 110	
GCT CTC CAA AGG TAT AAA GAT GGG AGC TTA ATC AAT CTT GGA TTC CCC	384
Ala Leu Gln Arg Tyr Lys Asp Gly Ser Leu Ile Asn Leu Gly Phe Pro	
115 120 125	
CCA GAA TCC TGC GGT TAT GCA ACA GTC ACA GAT TCT GAG GCA ATG TTG	432
Pro Glu Ser Cys Gly Tyr Ala Thr Val Thr Asp Ser Glu Ala Met Leu	
130 135 140	



GTC CAA GTG ACT CCC CAC CAC GTT GGG GTG GAT GAT TAT AGA GGT CAC Val Gln Val Thr Pro His His Val Gly Val Asp Asp Tyr Arg Gly His 145 150 155 160	480
TGG ATC GAC CCA CTA TTT CCA GGA GGA GAA TGC TCC ACC AAT TTT TGT Trp Ile Asp Pro Leu Phe Pro Gly Gly Glu Cys Ser Thr Asn Phe Cys 165 170 175	528
GAT ACA GTC CAC AAT TCA TCG GTG TGG ATC CCC AAG AGT CAA AAG ACT Asp Thr Val His Asn Ser Ser Val Trp Ile Pro Lys Ser Gln Lys Thr 180 185 190	576
GAC ATC TGT GCC CAG TCT TTC AAA AAT ATC AAG ATG ACC GCA TCT TAC Asp Ile Cys Ala Gln Ser Phe Lys Asn Ile Lys Met Thr Ala Ser Tyr 195 200 205	624
CCC TCA GAA GGA GCA TTG GTG AGT GAC AGA TTT GCC TTC CAC AGT GCA Pro Ser Glu Gly Ala Leu Val Ser Asp Arg Phe Ala Phe His Ser Ala 210 215 220	672
TAT CAT CCA AAT ATG CCG GGG TCA ACT GTT TGC ATA ATG GAC TTT TGC Tyr His Pro Asn Met Pro Gly Ser Thr Val Cys Ile Met Asp Phe Cys 225 230 235 240	720
GAA CAA AAG GGG TTG AGA TTC ACA AAT GGA GAG TGG ATG GGT CTC AAT Glu Gln Lys Gly Leu Arg Phe Thr Asn Gly Glu Trp Met Gly Leu Asn 245 250 255	768
GTG GAG CAA TCC ATC CGA GAG AAG AAG ATA AGT GCC ATC TTC CCA AAT Val Glu Gln Ser Ile Arg Glu Lys Lys Ile Ser Ala Ile Phe Pro Asn 260 265 270	816
TGT GTT GCA GGG ACT GAA ATC CGA GCC ACA CTA GAA TCA GAA GGG GCA Cys Val Ala Gly Thr Glu Ile Arg Ala Thr Leu Glu Ser Glu Gly Ala 275 280 285	864
AGA ACT TTG ACG TGG GAG ACT CAA AGA ATG CTA GAT TAC TCT TTG TGT Arg Thr Leu Thr Trp Glu Thr Gln Arg Met Leu Asp Tyr Ser Leu Cys 290 295 300	912
CAG AAC ACC TGG GAC AAA GTT TCC AGG AAA GAA CCT CTC AGT CCG CTT Gln Asn Thr Trp Asp Lys Val Ser Arg Lys Glu Pro Leu Ser Pro Leu 305 310 315 320	960
GAC TTG AGC TAT CTG TCA CCA AGG GCT CCA GGG AAA GGC ATG GCC TAT Asp Leu Ser Tyr Leu Ser Pro Arg Ala Pro Gly Lys Gly Met Ala Tyr 325 330 335	1008
ACC GTC ATA AAC GGA ACC CTG CAT TCG GCT CAT GCT AAA TAC ATT AGA Thr Val Ile Asn Gly Thr Leu His Ser Ala His Ala Lys Tyr Ile Arg 340 345 350	1056
ACC TGG ATT GAT TAT GGA GAA ATG AAG GAA ATT AAA GGT GGA CGT GGA Thr Trp Ile Asp Tyr Gly Glu Met Lys Glu Ile Lys Gly Gly Arg Gly 355 360 365	1104
GAA TAT TCC AAG GCT CCT GAG CTC CTC TGG TCC CAG TGG TTC GAT TTT Glu Tyr Ser Lys Ala Pro Glu Leu Leu Trp Ser Gln Trp Phe Asp Phe 370 375 380	1152
GGA CCG TTC AAA ATT GGA CCG AAT GGA CTC CTG CAC ACA GGG AAA ACC Gly Pro Phe Lys Ile Gly Pro Asn Gly Leu Leu His Thr Gly Lys Thr 385 390 395 400	1200
TTT AAA TTC CCT CTT TAT TTG ATC GGA GCA GGC ATA ATT GAC GAA GAT Phe Lys Phe Pro Leu Tyr Leu Ile Gly Ala Gly Ile Ile Asp Glu Asp 405 410 415	1248

CTG CAT GAA CTA GAT GAG GCT GCT CCC ATT GAT CAC CCA CAA ATG CCT Leu His Glu Leu Asp Glu Ala Ala Pro Ile Asp His Pro Gln Met Pro 420 425 430	1296
GAC GCG AAA AGC GTT CTT CCA GAA GAT GAA GAG ATA TTC TTC GGA GAC Asp Ala Lys Ser Val Leu Pro Glu Asp Glu Glu Ile Phe Phe Gly Asp 435 440 445	1344
ACA GGT GTA TCC AAA AAC CCT ATC GAG TTG ATT CAA GGA TGG TTC TCA Thr Gly Val Ser Lys Asn Pro Ile Glu Leu Ile Gln Gly Trp Phe Ser 450 455 460	1392
AAT TGG AGA GAG AGT GTA ATG GCA ATA GTC GGA ATT GTT CTA CTC ATC Asn Trp Arg Glu Ser Val Met Ala Ile Val Gly Ile Val Leu Leu Ile 465 470 475 480	1440
GTT GTG ACA TTT CTG GCG ATC AAG ACG GTC CGG GTG CTT AAT TGT CTC Val Val Thr Phe Leu Ala Ile Lys Thr Val Arg Val Leu Asn Cys Leu 485 490 495	1488
TGG AGA CCC AGA AAG AAA AGA ATC GTC AGA CAA GAA GTA GAT GTT GAA Trp Arg Pro Arg Lys Lys Arg Ile Val Arg Gln Glu Val Asp Val Glu 500 505 510	1536
TCC CGA CTA AAC CAT TTT GAG ATG AGA GGC TTT CCT GAA TAT GTT AAG Ser Arg Leu Asn His Phe Glu Met Arg Gly Phe Pro Glu Tyr Val Lys 515 520 525	1584
AGA TAA Arg	1590

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 529 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Asp Leu Phe Pro Ile Leu Val Val Val Leu Met Thr Asp Thr Val 1 5 10 15
Leu Gly Lys Phe Gln Ile Val Phe Pro Asp Gln Asn Glu Leu Glu Trp 20 25 30
Arg Pro Val Val Gly Asp Ser Arg His Cys Pro Gln Ser Ser Glu Met 35 40 45
Gln Phe Asp Gly Ser Arg Ser Gln Thr Ile Leu Thr Gly Lys Ala Pro 50 55 60
Val Gly Ile Thr Pro Ser Lys Ser Asp Gly Phe Ile Cys His Ala Ala 65 70 75 80
Lys Trp Val Thr Thr Cys Asp Phe Arg Trp Tyr Gly Pro Lys Tyr Ile 85 90 95
Thr His Ser Ile His His Leu Arg Pro Thr Thr Ser Asp Cys Glu Thr 100 105 110
Ala Leu Gln Arg Tyr Lys Asp Gly Ser Leu Ile Asn Leu Gly Phe Pro 115 120 125
Pro Glu Ser Cys Gly Tyr Ala Thr Val Thr Asp Ser Glu Ala Met Leu 130 135 140

Val Gln Val Thr Pro His His Val Gly Val Asp Asp Tyr Arg Gly His  
 145 150 155 160  
 Trp Ile Asp Pro Leu Phe Pro Gly Gly Glu Cys Ser Thr Asn Phe Cys  
 165 170 175  
 Asp Thr Val His Asn Ser Ser Val Trp Ile Pro Lys Ser Gln Lys Thr  
 180 185 190  
 Asp Ile Cys Ala Gln Ser Phe Lys Asn Ile Lys Met Thr Ala Ser Tyr  
 195 200 205  
 Pro Ser Glu Gly Ala Leu Val Ser Asp Arg Phe Ala Phe His Ser Ala  
 210 215 220  
 Tyr His Pro Asn Met Pro Gly Ser Thr Val Cys Ile Met Asp Phe Cys  
 225 230 235 240  
 Glu Gln Lys Gly Leu Arg Phe Thr Asn Gly Glu Trp Met Gly Leu Asn  
 245 250 255  
 Val Glu Gln Ser Ile Arg Glu Lys Lys Ile Ser Ala Ile Phe Pro Asn  
 260 265 270  
 Cys Val Ala Gly Thr Glu Ile Arg Ala Thr Leu Glu Ser Glu Gly Ala  
 275 280 285  
 Arg Thr Leu Thr Trp Glu Thr Gln Arg Met Leu Asp Tyr Ser Leu Cys  
 290 295 300  
 Gln Asn Thr Trp Asp Lys Val Ser Arg Lys Glu Pro Leu Ser Pro Leu  
 305 310 315 320  
 Asp Leu Ser Tyr Leu Ser Pro Arg Ala Pro Gly Lys Gly Met Ala Tyr  
 325 330 335  
 Thr Val Ile Asn Gly Thr Leu His Ser Ala His Ala Lys Tyr Ile Arg  
 340 345 350  
 Thr Trp Ile Asp Tyr Gly Glu Met Lys Glu Ile Lys Gly Gly Arg Gly  
 355 360 365  
 Glu Tyr Ser Lys Ala Pro Glu Leu Leu Trp Ser Gln Trp Phe Asp Phe  
 370 375 380  
 Gly Pro Phe Lys Ile Gly Pro Asn Gly Leu Leu His Thr Gly Lys Thr  
 385 390 395 400  
 Phe Lys Phe Pro Leu Tyr Leu Ile Gly Ala Gly Ile Ile Asp Glu Asp  
 405 410 415  
 Leu His Glu Leu Asp Glu Ala Ala Pro Ile Asp His Pro Gln Met Pro  
 420 425 430  
 Asp Ala Lys Ser Val Leu Pro Glu Asp Glu Glu Ile Phe Phe Gly Asp  
 435 440 445  
 Thr Gly Val Ser Lys Asn Pro Ile Glu Leu Ile Gln Gly Trp Phe Ser  
 450 455 460  
 Asn Trp Arg Glu Ser Val Met Ala Ile Val Gly Ile Val Leu Leu Ile  
 465 470 475 480  
 Val Val Thr Phe Leu Ala Ile Lys Thr Val Arg Val Leu Asn Cys Leu  
 485 490 495  
 Trp Arg Pro Arg Lys Lys Arg Ile Val Arg Gln Glu Val Asp Val Glu  
 500 505 510

Ser Arg Leu Asn His Phe Glu Met Arg Gly Phe Pro Glu Tyr Val Lys  
 515 520 525

Arg

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1569 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "DNA"

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1566

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATG AAT ATA CCT TGC TTT GCT GTG ATC CTC AGC TTA GCT ACT ACA CAT	48
Met Asn Ile Pro Cys Phe Ala Val Ile Leu Ser Leu Ala Thr Thr His	
1 5 10 15	
TCT CTG GGA GAA TTC CCC TTG TAT ACG ATT CCC GAG AAA ATA GAG AAA	96
Ser Leu Gly Glu Phe Pro Leu Tyr Thr Ile Pro Glu Lys Ile Glu Lys	
20 25 30	
TGG ACC CCC ATA GAC ATG ATC CAT CTT AGT TGC CCT AAT AAC ATG CTG	144
Trp Thr Pro Ile Asp Met Ile His Leu Ser Cys Pro Asn Asn Met Leu	
35 40 45	
TCT GAG GAA GAA GGT TGC AAT ACA GAG TCT CCT TTC ACC TAC TTC GAG	192
Ser Glu Glu Glu Gly Cys Asn Thr Glu Ser Pro Phe Thr Tyr Phe Glu	
50 55 60	
CTC AAG AGT GGT TAC CTA GCC CAT CAG AAG GTC CCA GGA TTT ACA TGC	240
Leu Lys Ser Gly Tyr Leu Ala His Gln Lys Val Pro Gly Phe Thr Cys	
65 70 75 80	
ACT GGG GTT GTG AAT GAG GCA GAG ACA TAC ACA AAC TTT GTC GGA TAT	288
Thr Gly Val Val Asn Glu Ala Glu Thr Tyr Thr Asn Phe Val Gly Tyr	
85 90 95	
GTC ACC ACC ACC TTC AAA AGG AAG CAC TTT AAA CCT ACA GTG GCT GCT	336
Val Thr Thr Thr Phe Lys Arg Lys His Phe Lys Pro Thr Val Ala Ala	
100 105 110	
TGT CGT GAT GCC TAC AAC TGG AAA GTA TCA GGG GAC CCC CGA TAT GAA	384
Cys Arg Asp Ala Tyr Asn Trp Lys Val Ser Gly Asp Pro Arg Tyr Glu	
115 120 125	
GAA TCT CTA CAC ACC CCG TAT CCC GAC AGC AGC TGG TTA AGG ACT GTG	432
Glu Ser Leu His Thr Pro Tyr Pro Asp Ser Ser Trp Leu Arg Thr Val	
130 135 140	
ACC ACA ACC AAA GAA GCC CTT CTT ATA ATA TCG CCA AGC ATT GTA GAG	480
Thr Thr Thr Lys Glu Ala Leu Leu Ile Ile Ser Pro Ser Ile Val Glu	
145 150 155 160	
ATG GAC ATA TAT GGC AGG ACC CTT CAC TCT CCC ATG TTC CCT TCG GGG	528
Met Asp Ile Tyr Gly Arg Thr Leu His Ser Pro Met Phe Pro Ser Gly	
165 170 175	
AAA TGT TCC AAG CTC TAT CCT TCT GTC CCC TCT TGT ACA ACC AAC CAT	576
Lys Cys Ser Lys Leu Tyr Pro Ser Val Pro Ser Cys Thr Thr Asn His	
180 185 190	

GAT TAC ACA TTG TGG TTG CCA GAA GAT TCT AGT CTG AGT TTG ATT TGC Asp Tyr Thr Leu Trp Leu Pro Glu Asp Ser Ser Leu Ser Leu Ile Cys 195 200 205	624
GAC ATC TTC ACT TCC AGC AGT GGA CAG AAG GCC ATG AAT GGG TCT CGC Asp Ile Phe Thr Ser Ser Ser Gly Gln Lys Ala Met Asn Gly Ser Arg 210 215 220	672
ATC TGC GGA TTC AAG GAT GAA AGG GGA TTT TAC AGA TCC TTG AAG GGA Ile Cys Gly Phe Lys Asp Glu Arg Gly Phe Tyr Arg Ser Leu Lys Gly 225 230 235 240	720
TCC TGT AAG CTG ACA TTG TGC GGG AAA CCT GGA ATT AGG CTG TTC GAC Ser Cys Lys Leu Thr Leu Cys Gly Lys Pro Gly Ile Arg Leu Phe Asp 245 250 255	768
GGA ACT TGG GTC TCT TTT ACA AAG CCG GAC GTT CAT GTG TGG TGC ACT Gly Thr Trp Val Ser Phe Thr Lys Pro Asp Val His Val Trp Cys Thr 260 265 270	816
CCC AAC CAG TTA GTC AAT ATA CAT AAC GAC AGA CTA GAT GAG GTT GAA Pro Asn Gln Leu Val Asn Ile His Asn Asp Arg Leu Asp Glu Val Glu 275 280 285	864
CAT CTG ATC GTG GAC GAT ATC ATC AAG AAG AGA GAG GAG TGT TTA GAC His Leu Ile Val Asp Asp Ile Ile Lys Lys Arg Glu Glu Cys Leu Asp 290 295 300	912
ACG CTG GAA ACT ATA CTT ATG TCT CAA TCA GTT AGT TTT AGA CGG TTG Thr Leu Glu Thr Ile Leu Met Ser Gln Ser Val Ser Phe Arg Arg Leu 305 310 315 320	960
AGC CAT TTC AGA AAG TTA GTT CCA GGA TAT GGA AAA GCT TAC ACT ATT Ser His Phe Arg Lys Leu Val Pro Gly Tyr Gly Lys Ala Tyr Thr Ile 325 330 335	1008
TTG AAC GGC AGC TTA ATG GAA ACA AAT GTC TAC TAC AAA AGA GTT GAC Leu Asn Gly Ser Leu Met Glu Thr Asn Val Tyr Tyr Lys Arg Val Asp 340 345 350	1056
AGG TGG GCG GAC ATT TTG CCT TCT AGG GGA TGT CTG AAA GTC GGA CAA Arg Trp Ala Asp Ile Leu Pro Ser Arg Gly Cys Leu Lys Val Gly Gln 355 360 365	1104
CAG TGC ATG GAC CCT GTC AAA GGG GTC CTC TTC AAC GGA ATT ATC AAG Gln Cys Met Asp Pro Val Lys Gly Val Leu Phe Asn Gly Ile Ile Lys 370 375 380	1152
GGT CCG GAT GGA CAA ATA TTG ATT CCA GAG ATG CAG TCA GAG CAG CTC Gly Pro Asp Gly Gln Ile Leu Ile Pro Glu Met Gln Ser Glu Gln Leu 385 390 395 400	1200
AAA CAG CAT ATG GAT CTG TTG AAA GCA GCT ATG TTT CCT CTC CGT CAT Lys Gln His Met Asp Leu Leu Lys Ala Ala Met Phe Pro Leu Arg His 405 410 415	1248
CCT TTA ATC AAC AGA GAG GCA GTC TTC AAG AAG GAT GGA AAT GCC GAT Pro Leu Ile Asn Arg Glu Ala Val Phe Lys Lys Asp Gly Asn Ala Asp 420 425 430	1296
GAT TTT GTT GAT CTC CAT ATG CCT GAT GTT CAA AAA TCT GTG TCG GAT Asp Phe Val Asp Leu His Met Pro Asp Val Gln Lys Ser Val Ser Asp 435 440 445	1344
GTC GAC CTG GGC CTG CCT CAT TGG GGG TTC TGG TTG TTA GTC GGG GCA Val Asp Leu Gly Leu Pro His Trp Gly Phe Trp Leu Leu Val Gly Ala 450 455 460	1392

ACA GTA GTA GCC TTT GTG GTC TTG GCG TGC TTG CTC CGT GTA TGT TGT 1440  
 Thr Val Val Ala Phe Val Val Leu Ala Cys Leu Leu Arg Val Cys Cys  
 465 470 475 480

AGG AGA ATG AGA AGG AGA AGG TCA CTG CGT GCC ACT CAG GAT ATC CCC 1488  
 Arg Arg Met Arg Arg Arg Ser Leu Arg Ala Thr Gln Asp Ile Pro  
 485 490 495

CTC AGC GTT GCC CCT GCC CCT GTC CCT CGT GCC AAA GTG GTG TCA TCA 1536  
 Leu Ser Val Ala Pro Ala Pro Val Pro Arg Ala Lys Val Val Ser Ser  
 500 505 510

TGG GAG TCT TCT AAA GGG CTC CCA GGT ACT TGA 1569  
 Trp Glu Ser Ser Lys Gly Leu Pro Gly Thr  
 515 520

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 522 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Asn Ile Pro Cys Phe Ala Val Ile Leu Ser Leu Ala Thr Thr His  
 1 5 10 15

Ser Leu Gly Glu Phe Pro Leu Tyr Thr Ile Pro Glu Lys Ile Glu Lys  
 20 25 30

Trp Thr Pro Ile Asp Met Ile His Leu Ser Cys Pro Asn Asn Met Leu  
 35 40 45

Ser Glu Glu Glu Gly Cys Asn Thr Glu Ser Pro Phe Thr Tyr Phe Glu  
 50 55 60

Leu Lys Ser Gly Tyr Leu Ala His Gln Lys Val Pro Gly Phe Thr Cys  
 65 70 75 80

Thr Gly Val Val Asn Glu Ala Glu Thr Tyr Thr Asn Phe Val Gly Tyr  
 85 90 95

Val Thr Thr Thr Phe Lys Arg Lys His Phe Lys Pro Thr Val Ala Ala  
 100 105 110

Cys Arg Asp Ala Tyr Asn Trp Lys Val Ser Gly Asp Pro Arg Tyr Glu  
 115 120 125

Glu Ser Leu His Thr Pro Tyr Pro Asp Ser Ser Trp Leu Arg Thr Val  
 130 135 140

Thr Thr Thr Lys Glu Ala Leu Leu Ile Ile Ser Pro Ser Ile Val Glu  
 145 150 155 160

Met Asp Ile Tyr Gly Arg Thr Leu His Ser Pro Met Phe Pro Ser Gly  
 165 170 175

Lys Cys Ser Lys Leu Tyr Pro Ser Val Pro Ser Cys Thr Thr Asn His  
 180 185 190

Asp Tyr Thr Leu Trp Leu Pro Glu Asp Ser Ser Leu Ser Leu Ile Cys  
 195 200 205

Asp Ile Phe Thr Ser Ser Ser Gly Gln Lys Ala Met Asn Gly Ser Arg  
 210 215 220

Ile Cys Gly Phe Lys Asp Glu Arg Gly Phe Tyr Arg Ser Leu Lys Gly  
 225 230 235 240  
 Ser Cys Lys Leu Thr Leu Cys Gly Lys Pro Gly Ile Arg Leu Phe Asp  
 245 250 255  
 Gly Thr Trp Val Ser Phe Thr Lys Pro Asp Val His Val Trp Cys Thr  
 260 265 270  
 Pro Asn Gln Leu Val Asn Ile His Asn Asp Arg Leu Asp Glu Val Glu  
 275 280 285  
 His Leu Ile Val Asp Asp Ile Ile Lys Lys Arg Glu Glu Cys Leu Asp  
 290 295 300  
 Thr Leu Glu Thr Ile Leu Met Ser Gln Ser Val Ser Phe Arg Arg Leu  
 305 310 315 320  
 Ser His Phe Arg Lys Leu Val Pro Gly Tyr Gly Lys Ala Tyr Thr Ile  
 325 330 335  
 Leu Asn Gly Ser Leu Met Glu Thr Asn Val Tyr Tyr Lys Arg Val Asp  
 340 345 350  
 Arg Trp Ala Asp Ile Leu Pro Ser Arg Gly Cys Leu Lys Val Gly Gln  
 355 360 365  
 Gln Cys Met Asp Pro Val Lys Gly Val Leu Phe Asn Gly Ile Ile Lys  
 370 375 380  
 Gly Pro Asp Gly Gln Ile Leu Ile Pro Glu Met Gln Ser Glu Gln Leu  
 385 390 395 400  
 Lys Gln His Met Asp Leu Leu Lys Ala Ala Met Phe Pro Leu Arg His  
 405 410 415  
 Pro Leu Ile Asn Arg Glu Ala Val Phe Lys Lys Asp Gly Asn Ala Asp  
 420 425 430  
 Asp Phe Val Asp Leu His Met Pro Asp Val Gln Lys Ser Val Ser Asp  
 435 440 445  
 Val Asp Leu Gly Leu Pro His Trp Gly Phe Trp Leu Leu Val Gly Ala  
 450 455 460  
 Thr Val Val Ala Phe Val Val Leu Ala Cys Leu Leu Arg Val Cys Cys  
 465 470 475 480  
 Arg Arg Met Arg Arg Arg Arg Ser Leu Arg Ala Thr Gln Asp Ile Pro  
 485 490 495  
 Leu Ser Val Ala Pro Ala Pro Val Pro Arg Ala Lys Val Val Ser Ser  
 500 505 510  
 Trp Glu Ser Ser Lys Gly Leu Pro Gly Thr  
 515 520

## CLAIMS

1. A composition comprising a non-human unfertilized oocyte comprising a heterologous oligonucleotide integrated into the genome of said oocyte.

5

2. The composition of Claim 1, wherein said unfertilized oocyte is a pre-maturation oocyte.

10

3. The composition of Claim 1, wherein said unfertilized oocyte is a pre-fertilization oocyte.

4. The composition of Claim 1, wherein said oligonucleotide is the proviral form of a retroviral vector.

15

5. The composition of Claim 1, wherein said non-human animal is a mammal.

6. The composition of Claim 1, wherein said mammal is a cow.

20

7. A method for introducing a heterologous polynucleotide into the genome of a non-human unfertilized oocyte, comprising:

a) providing:

i) a non-human unfertilized egg comprising an oocyte having a plasma membrane and a zona pellucida, said plasma membrane and said zona pellucida defining a perivitelline space;

25

ii) an aqueous solution comprising a heterologous polynucleotide; and

b) introducing said solution comprising said heterologous polynucleotide into said perivitelline space under conditions which permit the introduction of said heterologous polynucleotide into the genome of said oocyte.

30

8. The method of Claim 7, wherein said heterologous polynucleotide encodes a protein of interest.



9. The method of Claim 7, wherein said unfertilized oocyte is a pre-maturation oocyte.

10. The method of Claim 7, wherein said unfertilized oocyte is a pre-fertilization oocyte.

11. The method of Claim 7, wherein said heterologous polynucleotide is contained within genome of a recombinant retrovirus.

12. A method for the production of a transgenic non-human animal comprising:

a) providing:

i) an unfertilized egg comprising an oocyte having a plasma membrane and a zona pellucida, said plasma membrane and said zona pellucida defining a perivitelline space;

ii) an aqueous solution containing infectious retrovirus;

b) introducing said solution containing infectious retrovirus into said perivitelline space under conditions which permit the infection of said oocyte; and

c) contacting said infected oocyte with sperm under conditions which permit the fertilization of said infected oocyte to produce an embryo.

13. The method of Claim 12 further comprising following the fertilization of said infected oocyte the step of transferring said embryo into a hormonally synchronized non-human recipient animal.

14. The method of Claim 13 further comprising the step of allowing said embryo to develop to term.

15. The method of Claim 14 further comprising identifying at least one transgenic offspring.

16. The method of Claim 12, wherein said unfertilized egg comprises a pre-maturation oocyte.

17. The method of Claim 12, wherein said unfertilized egg comprises an pre-fertilization oocyte.

5 18. The method of Claim 16 further comprising following the introduction of said solution containing infectious retrovirus into said pre-maturation oocyte, the further step of culturing said infected pre-maturation oocyte under conditions which permit the maturation of said pre-maturation oocyte.

10 19. The method of Claim 12, wherein said infectious retrovirus comprises a heterologous membrane-associated protein.

20. The method of Claim 19, wherein said heterologous membrane-associated protein is a G glycoprotein selected from a virus within the family Rhabdoviridae.

15 21. The method of Claim 20, wherein said G glycoprotein is selected from the group comprising the G glycoprotein of vesicular stomatitis virus, Piry virus, Chandipura virus, Spring viremia of carp virus and Mokola virus.

20 22. The method of Claim 12, wherein said non-human animal is a mammal.

23. The method of Claim 22, wherein said mammal is a cow.







FIGURE 1






FIGURE 3

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05376

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :C12N 5/00, 5/10, 5/16, 15/00, 15/09

US CL :435/172.3, 325; 800/2, DIG 1, DIG 6

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.3, 325; 800/2, DIG 1, DIG 6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 90/08832 A1(NATIONAL RESEARCH DEVELOPMENT CORPORATION) 09 AUGUST 1990, See entire document.	1-23
X	US 5,523,222 (PAGE et al.) 04 June 1996, see entire document	1-18, 22 and 23
Y		19-21
X	US 4,664,097 (MCGRATH et al.) 12 May 1987, see entire document.	1-18, 22 and 23
Y		19-21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 APRIL 1998

Date of mailing of the international search report

17 JUL 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer,

Brian R. Stanton

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05376

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Databases: AGRICOLA, AIDSLINE, ANABSTR, AQUASCI, BIOBUSINESS, BIOSIS, BIOTECHDS, CABA, CANCERLIT, CAPLUS, CEABA, CEN, CIN, CJACS, CONFSCI, CROPB, CROPU, DOENE, DISSABS, DRUGB, DRUGLAUNCH, DRUGNL, DRUGU, EMBAL, EMBASE, FSTA, GENBANK, HEALSAFE, IFIPAT, JICST-EPLUS, MEDLINE

Search Terms: periv?; retrov?; transgen?; oocyt?; nucleic; acid; dna; ma; virus; transgen; bremel?/au; chan?/au; burns?/au

